{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:09:14Z","timestamp":1794665354285,"version":"4.9.1"},"reference-count":888,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/eurheartj\/ehag098","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:46:01Z","timestamp":1787921161000},"source":"Crossref","is-referenced-by-count":27,"title":["2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA)"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-2228","authenticated-orcid":false,"given":"Kevin","family":"Damman","sequence":"first","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-9336","authenticated-orcid":false,"given":"Jozine M","family":"ter Maaten","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5695-0270","authenticated-orcid":false,"given":"Kaitlin J","family":"Mayne","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3032-245X","authenticated-orcid":false,"given":"Davide","family":"Bolignano","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M","family":"Brown","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1786-6332","authenticated-orcid":false,"given":"Bruno R","family":"da Costa","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dagre","sequence":"additional","affiliation":[{"name":"(Greece)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-0906","authenticated-orcid":false,"given":"Ron T","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2553-8264","authenticated-orcid":false,"given":"Cristina","family":"Gavina","sequence":"additional","affiliation":[{"name":"(Portugal)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8223-7209","authenticated-orcid":false,"given":"Andreas","family":"Goette","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-1451","authenticated-orcid":false,"given":"Diana A","family":"Gorog","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Nikolova","family":"Gotcheva","sequence":"additional","affiliation":[{"name":"(Bulgaria)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-6247","authenticated-orcid":false,"given":"Marta","family":"Kaluzna-Oleksy","sequence":"additional","affiliation":[{"name":"(Poland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-2030","authenticated-orcid":false,"given":"Dearbhla M","family":"Kelly","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-4360","authenticated-orcid":false,"given":"Oleksii","family":"Korzh","sequence":"additional","affiliation":[{"name":"(Ukraine)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-0178","authenticated-orcid":false,"given":"Jennifer S","family":"Lees","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-2401","authenticated-orcid":false,"given":"Olivia","family":"Manfrini","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-2113","authenticated-orcid":false,"given":"Pieter","family":"Martens","sequence":"additional","affiliation":[{"name":"(Belgium)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-7119","authenticated-orcid":false,"given":"Julio","family":"Nunez","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9763-6010","authenticated-orcid":false,"given":"Eugenio","family":"Stabile","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8197-8892","authenticated-orcid":false,"given":"Isabella","family":"Sudano","sequence":"additional","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6216-9635","authenticated-orcid":false,"given":"Marieta P","family":"Theodorakopoulou","sequence":"additional","affiliation":[{"name":"(Greece)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8872-3681","authenticated-orcid":false,"given":"Simon","family":"Winther","sequence":"additional","affiliation":[{"name":"(Denmark)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1172-8243","authenticated-orcid":false,"given":"William G","family":"Herrington","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ESC Guidelines Advisory Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Evans","sequence":"additional","affiliation":[{"name":"(Sweden)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline M","family":"Van Craenenbroeck","sequence":"additional","affiliation":[{"name":"(Belgium)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleman","family":"Aktaa","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Amann","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W","family":"Asselbergs","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Borger","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Brida","sequence":"additional","affiliation":[{"name":"(Croatia)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Bruno","sequence":"additional","affiliation":[{"name":"(France)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Byrne","sequence":"additional","affiliation":[{"name":"(Ireland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Catherine","family":"Camaradou","sequence":"additional","affiliation":[{"name":"(United Kingdom\/Greece)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Clyne","sequence":"additional","affiliation":[{"name":"(Sweden)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"De Backer","sequence":"additional","affiliation":[{"name":"(Belgium)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Drenjan\u010devi\u0107","sequence":"additional","affiliation":[{"name":"(Croatia)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ekhart","sequence":"additional","affiliation":[{"name":"(Slovenia)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Gandjbakhch","sequence":"additional","affiliation":[{"name":"(France)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Grand","sequence":"additional","affiliation":[{"name":"(Denmark)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henner","family":"Hanssen","sequence":"additional","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Heidecker","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Iannaccone","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Ibanez","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"(Sweden)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Kouidi","sequence":"additional","affiliation":[{"name":"(Greece)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Malyszko","sequence":"additional","affiliation":[{"name":"(Poland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John William","family":"McEvoy","sequence":"additional","affiliation":[{"name":"(Republic of Ireland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borislava","family":"Mihaylova","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mindham","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Moelgaard","sequence":"additional","affiliation":[{"name":"(Denmark)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lis","family":"Neubeck","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Paolillo","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Parati","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Parolari","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Prescott","sequence":"additional","affiliation":[{"name":"(Denmark)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Quiroga","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Rossello","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubboli","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sannino","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sheppard","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Simpson","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix C","family":"Tanner","sequence":"additional","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M","family":"Valdivielso","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaryllis","family":"Van Craenenbroeck","sequence":"additional","affiliation":[{"name":"(Belgium)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda W","family":"van Laake","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Wood","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Zeppenfeld","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Henine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor R","family":"Ter-Grigoryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulvi","family":"Mirzoyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamija","family":"Ferhatbegovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliya Davidkova","family":"Demirevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jure","family":"Samard\u017ei\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mitsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilem","family":"Danzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Serg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Pohjant\u00e4hti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Mewton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaja","family":"Agladze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Bukosza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunna","family":"Snaedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Skalsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuela","family":"Carigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnara","family":"Junusbekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gani","family":"Bajraktari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Kerimkulova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlis","family":"Trusinskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souzan Mohamad Sabouh","family":"Tatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud H","family":"Abdou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigita","family":"Glaveckaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana A","family":"Banu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Cassar","family":"Demarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana Nicolae","family":"Priscu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El Minaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana Zafirovska","family":"Taleska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Vartdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Imiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Sofia","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Rimbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bertelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Ilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Cobo","family":"Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina Elisabeth","family":"Szummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamia","family":"Rais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganna D","family":"Radchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wheatcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigora Zaynutdinovna","family":"Srojidinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026102519571669700_ehag098-B1","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/eurheartj\/ehaf009","article-title":"2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention","volume":"46","author":"Juni","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B2","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehaf016","article-title":"2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models","volume":"46","author":"Di Angelantonio","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B4","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Writing Group for the CKD Prognosis Consortium","year":"2023","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B5","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/S0140-6736(25)00548-3","article-title":"Reducing the burden of chronic kidney disease in the world","volume":"405","author":"Lou-Meda","year":"2025","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B6","doi-asserted-by":"crossref","DOI":"10.1201\/9780429460418","volume-title":"The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal Practitioners","author":"Ashley","year":"2018"},{"key":"2026102519571669700_ehag098-B7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.asn.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1053\/j.ajkd.2013.10.043","article-title":"The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov","volume":"63","author":"Inrig","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B9","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease Improving Global Outcomes CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.5414\/cn108525","article-title":"Diagnostic accuracy of serum cystatin C in chronic kidney disease: a meta-analysis","volume":"84","author":"Wei","year":"2015","journal-title":"Clin Nephrol"},{"key":"2026102519571669700_ehag098-B12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/gfac254","article-title":"What should European nephrology do with the new CKD-EPI equation?","volume":"38","author":"Gansevoort","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/ndt\/gfac241","article-title":"Performance of creatinine-based equations to estimate glomerular filtration rate in White and Black populations in Europe, Brazil and Africa","volume":"38","author":"Delanaye","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.7326\/M20-4366","article-title":"Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate: a cross-sectional analysis of pooled data","volume":"174","author":"Pottel","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B16","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/ckj\/sfad039","article-title":"New and old GFR equations: a European perspective","volume":"16","author":"Delanaye","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026102519571669700_ehag098-B17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","article-title":"Measurement and estimation of GFR for use in clinical practice: core curriculum 2021","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/MNH.0000000000001022","article-title":"Serum creatinine and serum cystatin C as an index of muscle mass in adults","volume":"33","author":"Liu","year":"2024","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026102519571669700_ehag098-B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/HYHN1078","article-title":"Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study","volume":"28","author":"Lamb","year":"2024","journal-title":"Health Technol Assess"},{"key":"2026102519571669700_ehag098-B20","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/jcsm.13511","article-title":"Creatinine, cystatin C, muscle mass, and mortality: findings from a primary and replication population-based cohort","volume":"15","author":"Groothof","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026102519571669700_ehag098-B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1681\/ASN.2008030292","article-title":"First morning voids are more reliable than spot urine samples to assess microalbuminuria","volume":"20","author":"Witte","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e08253","article-title":"Diagnostic accuracy of urine dipstick testing for albumin-to-creatinine ratio and albuminuria: a systematic review and meta-analysis","volume":"7","author":"Mejia","year":"2021","journal-title":"Heliyon"},{"key":"2026102519571669700_ehag098-B25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B26","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100552","article-title":"Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets","volume":"27","author":"Matsushita","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026102519571669700_ehag098-B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/eurjpc\/zwac176","article-title":"Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP","volume":"30","author":"Matsushita","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519571669700_ehag098-B30","author":"United States Renal Data System"},{"key":"2026102519571669700_ehag098-B31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B32","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MNH.0b013e3282f88a1f","article-title":"Hypertensive nephrosclerosis","volume":"17","author":"Hill","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026102519571669700_ehag098-B34","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B35","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2024.07.009","article-title":"KDIGO 2025 Clinical Practice Guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD)","volume":"107","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group","year":"2025","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B36","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2367021","article-title":"Noninvasive diagnosis of interstitial fibrosis in chronic kidney disease: a systematic review and meta-analysis","volume":"46","author":"Wan","year":"2024","journal-title":"Ren Fail"},{"key":"2026102519571669700_ehag098-B37","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/jcdd11020062","article-title":"Cardiac and renal fibrosis, the silent killer in the cardiovascular continuum: an up-to-date","volume":"11","author":"Chiuariu","year":"2024","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026102519571669700_ehag098-B39","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/ndt\/gfaa284","article-title":"Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis","volume":"37","author":"Romero-Gonzalez","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B40","first-page":"776","article-title":"Chronic kidney disease: detection and evaluation","volume":"96","author":"Gaitonde","year":"2017","journal-title":"Am Fam Physician"},{"key":"2026102519571669700_ehag098-B41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000158526","article-title":"Early detection of chronic kidney disease: results of the PolNef study","volume":"29","author":"Krol","year":"2009","journal-title":"Am J Nephrol"},{"key":"2026102519571669700_ehag098-B43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12882-022-02677-y","article-title":"Using dipstick urinalysis to predict development of acute kidney injury in patients with COVID-19","volume":"23","author":"McAdams","year":"2022","journal-title":"BMC Nephrol"},{"key":"2026102519571669700_ehag098-B44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1515\/abm-2020-0028","article-title":"Diagnostic performance of renal ultrasonography in detecting chronic kidney disease of various severity","volume":"14","author":"Kodikara","year":"2020","journal-title":"Asian Biomed"},{"key":"2026102519571669700_ehag098-B45","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4241","article-title":"Role of ultrasound in the diagnosis of chronic kidney disease and its correlation with serum creatinine level","volume":"11","author":"Ahmed","year":"2019","journal-title":"Cureus"},{"key":"2026102519571669700_ehag098-B46","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa0905368","article-title":"Revascularization versus medical therapy for renal-artery stenosis","volume":"361","author":"Astral Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1310753","article-title":"Stenting and medical therapy for atherosclerotic renal-artery stenosis","volume":"370","author":"Cooper","year":"2014","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B48","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1161\/HYP.0000000000000217","article-title":"Revascularization for renovascular disease: a scientific statement from the American Heart Association","volume":"79","author":"Bhalla","year":"2022","journal-title":"Hypertension"},{"key":"2026102519571669700_ehag098-B49","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520983585","article-title":"Use of percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis: a systematic review and meta-analysis","volume":"49","author":"Chen","year":"2021","journal-title":"J Int Med Res"},{"key":"2026102519571669700_ehag098-B50","doi-asserted-by":"publisher","first-page":"544","DOI":"10.6515\/ACS.202409_40(5).20240731A","article-title":"2024 Update of the TSOC expert consensus of Fabry disease","volume":"40","author":"Hung","year":"2024","journal-title":"Acta Cardiol Sin"},{"key":"2026102519571669700_ehag098-B51","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B52","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B53","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/MNH.0000000000000907","article-title":"Medication safety in chronic kidney disease","volume":"32","author":"Singh","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026102519571669700_ehag098-B54","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1053\/j.ajkd.2018.06.011","article-title":"The validity of drug effects on proteinuria, albuminuria, serum creatinine, and estimated GFR as surrogate end points for ESKD: a systematic review","volume":"72","author":"Palmer","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B55","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1681\/ASN.0000000000000117","article-title":"Change in albuminuria and GFR slope as joint surrogate end points for kidney failure: implications for phase 2 clinical trials in CKD","volume":"34","author":"Heerspink","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B56","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.2215\/CJN.00580118","article-title":"Medication safety principles and practice in CKD","volume":"13","author":"Whittaker","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B57","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12875-022-01931-4","article-title":"Appropriateness of drug prescriptions in patients with chronic kidney disease in primary care: a double-center retrospective study","volume":"23","author":"Ruiz-Boy","year":"2022","journal-title":"BMC Prim Care"},{"key":"2026102519571669700_ehag098-B58","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.015969","article-title":"Use of QT prolonging medications by hemodialysis patients and individuals without end-stage kidney disease","volume":"9","author":"Assimon","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/ndt\/gfl587","article-title":"Sudden cardiac death in nephrology: focus on acquired long QT syndrome","volume":"22","author":"Gussak","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B60","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.metabol.2005.11.004","article-title":"Body surface area in normal-weight, overweight, and obese adults. A comparison study","volume":"55","author":"Verbraecken","year":"2006","journal-title":"Metabolism"},{"key":"2026102519571669700_ehag098-B61","author":"U.S. Food & Drug Administration (FDA)"},{"key":"2026102519571669700_ehag098-B62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010612.pub3","article-title":"Timing of kidney replacement therapy initiation for acute kidney injury","volume":"11","author":"Fayad","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B63","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1053\/j.ajkd.2021.07.014","article-title":"Timing of kidney support therapy in acute kidney injury: what are we waiting for?","volume":"79","author":"Bouchard","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B64","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/imj.16377","article-title":"Use of kidney failure risk equation as a tool to evaluate referrals from primary care to specialist nephrology care","volume":"54","author":"Li","year":"2024","journal-title":"Intern Med J"},{"key":"2026102519571669700_ehag098-B65","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/eurheartj\/ehac825","article-title":"Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study","volume":"44","author":"Mark","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B66","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.ajkd.2018.08.013","article-title":"Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta-analysis in a global consortium","volume":"73","author":"Inker","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B67","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B68","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1053\/j.akdh.2024.08.003","article-title":"Utilization of potassium binders for the management of hyperkalemia in chronic kidney disease: a position statement by US nephrologists","volume":"31","author":"Rastogi","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"2026102519571669700_ehag098-B69","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B70","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B71","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B72","author":"Kidney Disease: Improving Global Outcomes (KDIGO)"},{"key":"2026102519571669700_ehag098-B73","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","article-title":"Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"107","author":"Ketteler","year":"2025","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B74","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.ekir.2021.05.012","article-title":"Phosphate balance and CKD-mineral bone disease","volume":"6","author":"Sprague","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026102519571669700_ehag098-B75","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1681\/ASN.2008040349","article-title":"Association of serum phosphate with vascular and valvular calcification in moderate CKD","volume":"20","author":"Adeney","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B76","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B77","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2215\/CJN.0000000000000487","article-title":"Sodium bicarbonate treatment and clinical outcomes in chronic kidney disease with metabolic acidosis: a meta-analysis","volume":"19","author":"Yang","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B78","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f324","article-title":"Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis","volume":"346","author":"Nitsch","year":"2013","journal-title":"BMJ"},{"key":"2026102519571669700_ehag098-B79","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/ki.2013.553","article-title":"Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar","volume":"86","author":"Wen","year":"2014","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B80","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B81","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1681\/ASN.2020040476","article-title":"Slope of kidney function and its association with longitudinal mortality and cardiovascular disease among individuals with CKD","volume":"31","author":"Orlandi","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B82","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1111\/dom.15817","article-title":"Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: an analysis of the EXSCEL trial","volume":"26","author":"Oulhaj","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026102519571669700_ehag098-B83","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023594","article-title":"Is there a correlation between an eGFR slope measured over a 5-year period and incident cardiovascular events in the following 5 years among a Flemish general practice population: a retrospective cohort study","volume":"8","author":"Van Pottelbergh","year":"2018","journal-title":"BMJ Open"},{"key":"2026102519571669700_ehag098-B84","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12933-021-01247-0","article-title":"Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease","volume":"20","author":"Hubbard","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026102519571669700_ehag098-B85","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s12561-024-09429-6","article-title":"A Bayesian joint model of longitudinal kidney disease progression, recurrent cardiovascular events, and terminal event in patients with chronic kidney disease","volume":"17","author":"Kurum","year":"2025","journal-title":"Stat Biosci"},{"key":"2026102519571669700_ehag098-B86","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B87","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 Working Group and ESC Cardiovascular Risk Collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B88","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","article-title":"SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe","volume":"44","author":"SCORE2-Diabetes Working Group of the ESC Cardiovascular Risk Collaboration","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B89","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm","volume":"43","author":"Hageman","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B90","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030757","article-title":"Validating the SMART2 score in a racially diverse high-risk nationwide cohort of patients receiving coronary artery bypass grafting","volume":"12","author":"Deo","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B91","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag154","article-title":"Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model","author":"SCORE2 Writing Group","year":"2026","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B92","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag153","article-title":"Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model","author":"Reitsma","year":"2026","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B93","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B94","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag182","article-title":"Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model","author":"Reitsma","year":"2026","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B95","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.ajkd.2014.09.016","article-title":"Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"65","author":"Ricardo","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B96","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1053\/j.ajkd.2016.02.052","article-title":"Smoking and adverse outcomes in patients with CKD: the Study of Heart and Renal Protection (SHARP)","volume":"68","author":"Staplin","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B97","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B98","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1136\/bmj.38142.554479.AE","article-title":"Mortality in relation to smoking: 50 years\u2019 observations on male British doctors","volume":"328","author":"Doll","year":"2004","journal-title":"BMJ"},{"key":"2026102519571669700_ehag098-B99","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1001\/jama.290.1.86","article-title":"Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review","volume":"290","author":"Critchley","year":"2003","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B100","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/0003-4819-142-4-200502150-00005","article-title":"The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial","volume":"142","author":"Anthonisen","year":"2005","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008286.pub3","article-title":"Combined pharmacotherapy and behavioural interventions for smoking cessation","volume":"3","author":"Stead","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B102","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/11537850-000000000-00000","article-title":"A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation","volume":"49","author":"Faessel","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2026102519571669700_ehag098-B103","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1067\/mcp.2000.109006","article-title":"Pharmacokinetics of nicotine in kidney failure","volume":"68","author":"Molander","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"2026102519571669700_ehag098-B104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013119.pub2","article-title":"Interventions for weight loss in people with chronic kidney disease who are overweight or obese","volume":"3","author":"Conley","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B105","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S2213-8587(14)70156-1","article-title":"Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial","volume":"2","author":"Look AHEAD Research Group","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B106","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.euf.2023.11.003","article-title":"Effect of recipient body mass index on kidney transplantation outcomes: a systematic review and meta-analysis by the Transplant Committee from the French Association of Urology","volume":"10","author":"Prudhomme","year":"2024","journal-title":"Eur Urol Focus"},{"key":"2026102519571669700_ehag098-B107","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/ndt\/gfab310","article-title":"Management of obesity in kidney transplant candidates and recipients: a clinical practice guideline by the DESCARTES Working Group of ERA","volume":"37","author":"Oniscu","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B108","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2022.05.007","article-title":"Self-reported physical activity and cardiovascular events in adults with CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) study","volume":"80","author":"Bruinius","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B109","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/eurjpc\/zwaa162","article-title":"Dose-response effects of physical activity on all-cause mortality and major cardiorenal outcomes in chronic kidney disease","volume":"29","author":"Kuo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519571669700_ehag098-B110","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2215\/CJN.08410814","article-title":"Light-intensity physical activities and mortality in the United States general population and CKD subpopulation","volume":"10","author":"Beddhu","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B111","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1681\/ASN.2016030378","article-title":"Exercise in patients on dialysis: a multicenter, randomized clinical trial","volume":"28","author":"Manfredini","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B112","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300057","article-title":"Exercise during hemodialysis in patients with chronic kidney failure","volume":"2","author":"Anding-Rost","year":"2023","journal-title":"NEJM Evid"},{"key":"2026102519571669700_ehag098-B113","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ekir.2019.04.001","article-title":"Randomized controlled trial of exercise in CKD\u2014the RENEXC study","volume":"4","author":"Hellberg","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2026102519571669700_ehag098-B114","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1681\/ASN.2021050668","article-title":"Effect of a 3-year lifestyle intervention in patients with chronic kidney disease: a randomized clinical trial","volume":"33","author":"Beetham","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B115","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2215\/CJN.12300720","article-title":"Targeting sedentary behavior in CKD: a pilot and feasibility randomized controlled trial","volume":"16","author":"Lyden","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B116","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/j.ajkd.2014.03.020","article-title":"Exercise training in adults with CKD: a systematic review and meta-analysis","volume":"64","author":"Heiwe","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B117","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/eurheartj\/ehaa605","article-title":"2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease","volume":"42","author":"Pelliccia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B118","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/eurjpc\/zwae130","article-title":"The role of exercise training on cardiovascular risk factors and heart disease in patients with chronic kidney disease G3-G5 and G5D: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the European Association of Rehabilitation in Chronic Kidney Disease","volume":"31","author":"Kouidi","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519571669700_ehag098-B119","author":"World Health Organization (WHO)"},{"key":"2026102519571669700_ehag098-B120","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B121","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJMoa2105675","article-title":"Effect of salt substitution on cardiovascular events and death","volume":"385","author":"Neal","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010070.pub3","article-title":"Altered dietary salt intake for people with chronic kidney disease","volume":"6","author":"McMahon","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B123","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ki.2012.74","article-title":"Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers","volume":"82","author":"Lambers Heerspink","year":"2012","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B124","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050843","article-title":"Effect of a low-salt diet on chronic kidney disease outcomes: a systematic review and meta-analysis","volume":"12","author":"Shi","year":"2022","journal-title":"BMJ Open"},{"key":"2026102519571669700_ehag098-B125","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/advances\/nmaa027","article-title":"Dietary potassium intake and risk of chronic kidney disease progression in predialysis patients with chronic kidney disease: a systematic review","volume":"11","author":"Picard","year":"2020","journal-title":"Adv Nutr"},{"key":"2026102519571669700_ehag098-B126","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k5301","article-title":"Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium","volume":"364","author":"Chang","year":"2019","journal-title":"BMJ"},{"key":"2026102519571669700_ehag098-B127","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5680","article-title":"Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials","volume":"347","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2013","journal-title":"BMJ"},{"key":"2026102519571669700_ehag098-B128","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1053\/j.ajkd.2015.08.027","article-title":"Hypertension and prehypertension and prediction of development of decreased estimated GFR in the general population: a meta-analysis of cohort studies","volume":"67","author":"Garofalo","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B129","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.ajkd.2013.07.024","article-title":"Prehypertension and incidence of ESRD: a systematic review and meta-analysis","volume":"63","author":"Huang","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","article-title":"2024 European Society of Hypertension Clinical Practice Guidelines for the management of arterial hypertension","volume":"126","author":"Kreutz","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026102519571669700_ehag098-B131","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026102519571669700_ehag098-B132","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B133","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1161\/HYPERTENSIONAHA.119.12697","article-title":"Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients","volume":"73","author":"Aggarwal","year":"2019","journal-title":"Hypertension"},{"key":"2026102519571669700_ehag098-B134","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B135","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1001\/jamainternmed.2017.0197","article-title":"Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis","volume":"177","author":"Tsai","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2026102519571669700_ehag098-B136","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1503\/cmaj.121468","article-title":"Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"185","author":"Lv","year":"2013","journal-title":"CMAJ"},{"key":"2026102519571669700_ehag098-B137","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1159\/000531029","article-title":"What is wrong with the blood pressure target recommendation of KDIGO 2021 for hypertension in chronic kidney disease?","volume":"147","author":"Jamale","year":"2023","journal-title":"Nephron"},{"key":"2026102519571669700_ehag098-B138","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B139","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/08037051.2021.1995981","article-title":"Attended vs. unattended blood pressure \u2013 learnings beyond SPRINT","volume":"30","author":"Kjeldsen","year":"2021","journal-title":"Blood Press"},{"key":"2026102519571669700_ehag098-B140","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >\/=75 years: a randomized clinical trial","volume":"315","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B141","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","author":"Sprint Research Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B142","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120\u2005mm Hg versus less than 140\u2005mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B143","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0140-6736(25)01391-1","article-title":"Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials","volume":"406","author":"Guo","year":"2025","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B144","doi-asserted-by":"publisher","first-page":"375","DOI":"10.7326\/M16-2966","article-title":"Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial","volume":"167","author":"Beddhu","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B145","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1681\/ASN.2018121261","article-title":"Implications of early decline in eGFR due to intensive BP control for cardiovascular outcomes in SPRINT","volume":"30","author":"Beddhu","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B146","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1681\/ASN.0000000000000072","article-title":"Intensive BP control in patients with CKD and risk for adverse outcomes","volume":"34","author":"Ku","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B147","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/jamainternmed.2017.4377","article-title":"Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis","volume":"177","author":"Malhotra","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2026102519571669700_ehag098-B148","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B149","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008564.pub3","article-title":"Blood pressure targets for hypertension in people with chronic renal disease","volume":"10","author":"Erviti","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B150","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/ndt\/gfae041","article-title":"A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension","volume":"39","author":"Sarafidis","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B151","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40885-023-00238-5","article-title":"Therapeutic roles of thiazides and loop diuretics in blood pressure control and renal protection against chronic kidney disease","volume":"29","author":"Jo","year":"2023","journal-title":"Clin Hypertens"},{"key":"2026102519571669700_ehag098-B152","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B153","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/hr.2014.110","article-title":"Impact of combined losartan\/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension","volume":"37","author":"Fujisaki","year":"2014","journal-title":"Hypertens Res"},{"key":"2026102519571669700_ehag098-B154","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100643","article-title":"Lifestyle interventions, kidney disease progression, and quality of life: a systematic review and meta-analysis","volume":"5","author":"Neale","year":"2023","journal-title":"Kidney Med"},{"key":"2026102519571669700_ehag098-B156","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/0886022X.2021.1920427","article-title":"Effects of intensive blood pressure control on mortality and cardiorenal function in chronic kidney disease patients","volume":"43","author":"Zhang","year":"2021","journal-title":"Ren Fail"},{"key":"2026102519571669700_ehag098-B157","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","article-title":"Intensive blood-pressure control in patients with type 2 diabetes","volume":"392","author":"Bi","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B158","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/jch.14795","article-title":"Does home blood pressure monitoring improve blood pressure-related outcomes in people living with chronic kidney disease? A systematic review","volume":"26","author":"Carey","year":"2024","journal-title":"J Clin Hypertens"},{"key":"2026102519571669700_ehag098-B159","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1001\/archinternmed.2011.230","article-title":"Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease","volume":"171","author":"Minutolo","year":"2011","journal-title":"Arch Intern Med"},{"key":"2026102519571669700_ehag098-B160","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41440-024-02080-0","article-title":"Prognostic value of nighttime blood pressure in patients with chronic kidney disease","volume":"48","author":"Li","year":"2025","journal-title":"Hypertens Res"},{"key":"2026102519571669700_ehag098-B161","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B162","doi-asserted-by":"publisher","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026102519571669700_ehag098-B163","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2215\/CJN.03390807","article-title":"Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis","volume":"3","author":"de Boer","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1542-4758.2006.01168.x","article-title":"Mechanisms of dyslipidemia of chronic renal failure","volume":"10","author":"Vaziri","year":"2006","journal-title":"Hemodial Int"},{"key":"2026102519571669700_ehag098-B165","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrneph.2015.180","article-title":"HDL abnormalities in nephrotic syndrome and chronic kidney disease","volume":"12","author":"Vaziri","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2026102519571669700_ehag098-B166","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/0886022X.2011.641515","article-title":"Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis","volume":"34","author":"Samouilidou","year":"2012","journal-title":"Ren Fail"},{"key":"2026102519571669700_ehag098-B167","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B168","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B169","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B170","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (Chronic Renal Insufficiency Cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026102519571669700_ehag098-B171","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"key":"2026102519571669700_ehag098-B172","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B173","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B174","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12944-023-01833-z","article-title":"International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?","volume":"22","author":"Calice-Silva","year":"2023","journal-title":"Lipids Health Dis"},{"key":"2026102519571669700_ehag098-B175","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B176","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1053\/j.ajkd.2015.09.020","article-title":"Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP)","volume":"67","author":"Mihaylova","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B177","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B178","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijcard.2006.06.003","article-title":"The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials","volume":"117","author":"Holdaas","year":"2007","journal-title":"Int J Cardiol"},{"key":"2026102519571669700_ehag098-B179","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B180","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B181","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B182","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B183","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","article-title":"Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention\u2013an Intervention Trial Evaluating Rosuvastatin) trial","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B184","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B185","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B186","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"key":"2026102519571669700_ehag098-B187","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005019.pub4","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","volume":"2014","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B188","author":"Electronic Medicines Compendium"},{"key":"2026102519571669700_ehag098-B189","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","article-title":"Management of dyslipidemia in adult solid organ transplant recipients","volume":"13","author":"Warden","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2026102519571669700_ehag098-B190","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.ekir.2023.05.008","article-title":"Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)","volume":"8","author":"Herrington","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026102519571669700_ehag098-B191","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B192","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2026102519571669700_ehag098-B193","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B194","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007784.pub3","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"11","author":"Tunnicliffe","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B195","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B196","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B197","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1681\/ASN.2020101440","article-title":"Platelet function in CKD: a systematic review and meta-analysis","volume":"32","author":"Baaten","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2025.101355","article-title":"Impaired secondary platelet response in chronic kidney disease as a consequence of prior platelet activation","volume":"10","author":"Baaten","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"2026102519571669700_ehag098-B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2025.101358","article-title":"Primed to fail: exhausted platelets in chronic kidney disease","volume":"10","author":"Roweth","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"2026102519571669700_ehag098-B200","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B201","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","article-title":"Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER study)","volume":"32","author":"Goicoechea","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026102519571669700_ehag098-B202","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2337\/dc10-1615","article-title":"Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial","volume":"34","author":"Saito","year":"2011","journal-title":"Diabetes Care"},{"key":"2026102519571669700_ehag098-B203","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jacc.2010.02.068","article-title":"Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial","volume":"56","author":"Jardine","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B204","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.kint.2020.08.011","article-title":"Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease","volume":"99","author":"Wolfe","year":"2021","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B205","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2022.09.023","article-title":"Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease","volume":"103","author":"Mann","year":"2023","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B206","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2016.06.013","article-title":"Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: a meta-analysis","volume":"251","author":"Major","year":"2016","journal-title":"Atherosclerosis"},{"key":"2026102519571669700_ehag098-B207","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/eurjpc\/zwab132","article-title":"Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis","volume":"28","author":"Pallikadavath","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519571669700_ehag098-B208","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40256-024-00630-y","article-title":"Aspirin for the primary prevention of cardiovascular diseases in patients with chronic kidney disease: an updated meta-analysis","volume":"24","author":"Bellos","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026102519571669700_ehag098-B209","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13063-022-06132-z","article-title":"Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease","volume":"23","author":"Gallagher","year":"2022","journal-title":"Trials"},{"key":"2026102519571669700_ehag098-B210","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B211","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B212","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B213","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B214","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2337\/dc06-1998","article-title":"Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes","volume":"30","author":"Makino","year":"2007","journal-title":"Diabetes Care"},{"key":"2026102519571669700_ehag098-B215","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B216","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B217","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B218","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B219","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B220","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1053\/j.ajkd.2012.07.011","article-title":"Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial","volume":"61","author":"Fernandez Juarez","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B221","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B222","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","article-title":"Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies","volume":"123","author":"Tobe","year":"2011","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B223","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1097\/HJH.0b013e32830508aa","article-title":"Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial","volume":"26","author":"Menne","year":"2008","journal-title":"J Hypertens"},{"key":"2026102519571669700_ehag098-B224","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B225","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B226","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B227","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B228","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B229","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B230","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","author":"Empa-Kidney Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B231","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B232","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103338","article-title":"Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial","volume":"85","author":"Zhou","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026102519571669700_ehag098-B233","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2215\/CJN.03790322","article-title":"Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD","volume":"17","author":"McEwan","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B234","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"Empa-Kidney Collaborative Group","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B235","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1681\/ASN.0000000000000271","article-title":"Effects of empagliflozin on fluid overload, weight, and blood pressure in CKD","volume":"35","author":"Mayne","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B236","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B237","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B238","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B239","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B240","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"2026102519571669700_ehag098-B241","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007004.pub4","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B242","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B243","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B244","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026102519571669700_ehag098-B245","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B246","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"2026102519571669700_ehag098-B247","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"2026102519571669700_ehag098-B248","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B249","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B250","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B251","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B252","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2026102519571669700_ehag098-B253","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026102519571669700_ehag098-B254","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"2026102519571669700_ehag098-B255","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B256","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B257","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zoungas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B258","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"2026102519571669700_ehag098-B259","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","article-title":"Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)","volume":"404","author":"Adler","year":"2024","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B260","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","article-title":"Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management","volume":"7","author":"International Hypoglycaemia Study Group","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102519571669700_ehag098-B261","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"2026102519571669700_ehag098-B262","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B263","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B264","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"key":"2026102519571669700_ehag098-B265","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40262-013-0046-9","article-title":"Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function","volume":"52","author":"Duong","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2026102519571669700_ehag098-B266","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2026102519571669700_ehag098-B267","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s0140-6736(07)60106-8","article-title":"Adjudication of serious heart failure in patients from PROactive","volume":"369","author":"Ryd\u00e9n","year":"2007","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B268","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B269","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec versus glargine in type 2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B270","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Origin Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B271","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/dom.16147","article-title":"Assessing the benefit-risk profile of newer glucose-lowering drugs: a systematic review and network meta-analysis of randomized outcome trials","volume":"27","author":"Tang","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026102519571669700_ehag098-B272","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B273","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B274","doi-asserted-by":"publisher","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","article-title":"Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations","volume":"154","author":"Bennett","year":"2011","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B275","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Advance Collaborative Group","year":"2008","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B276","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B277","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.amjmed.2018.02.023","article-title":"Alogliptin in patients with type 2 diabetes receiving metformin and sulfonylurea therapies in the EXAMINE trial","volume":"131","author":"White","year":"2018","journal-title":"Am J Med"},{"key":"2026102519571669700_ehag098-B278","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B279","doi-asserted-by":"publisher","author":"K\u00f8ber","DOI":"10.1093\/eurheartj\/ehag100"},{"key":"2026102519571669700_ehag098-B280","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B281","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ejhf.2848","article-title":"Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society","volume":"25","author":"Tsutsui","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B282","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/j.ajkd.2021.06.017","article-title":"Upper reference limits for high-sensitivity cardiac troponin T and N-terminal fragment of the prohormone brain natriuretic peptide in patients with CKD","volume":"79","author":"Bansal","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B283","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1681\/ASN.2014010108","article-title":"High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"26","author":"Bansal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B284","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0272-6386(04)00812-1","article-title":"Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF","volume":"44","author":"Takami","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B285","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/eci.12234","article-title":"Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship","volume":"44","author":"Takase","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"2026102519571669700_ehag098-B286","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2369-14-117","article-title":"B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function","volume":"14","author":"Jafri","year":"2013","journal-title":"BMC Nephrol"},{"key":"2026102519571669700_ehag098-B287","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jchf.2015.07.014","article-title":"Amino-terminal pro-B-type natriuretic peptide for diagnosis and prognosis in patients with renal dysfunction: a systematic review and meta-analysis","volume":"3","author":"Schaub","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B288","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B289","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102581","article-title":"Heart failure in advanced chronic kidney disease: overlooked no more","volume":"13","author":"de la Espriella","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B290","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jchf.2024.01.004","article-title":"Trajectories of kidney function in heart failure over a 15-year follow-up: clinical profiling and mortality","volume":"12","author":"Zamora","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B291","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jchf.2023.01.029","article-title":"Chronic kidney disease, heart failure, and adverse cardiac remodeling in older adults: the ARIC study","volume":"11","author":"Buckley","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B292","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jchf.2019.01.016","article-title":"Association of urine albumin excretion with incident heart failure hospitalization in community-dwelling adults","volume":"7","author":"Bailey","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B293","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamacardio.2017.4987","article-title":"Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction","volume":"3","author":"de Boer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026102519571669700_ehag098-B294","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ejhf.778","article-title":"The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction","volume":"19","author":"Nayor","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B295","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart failure: JACC state-of-the-art review","volume":"75","author":"Felker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B296","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","article-title":"Combination of loop diuretics with thiazide-type diuretics in heart failure","volume":"56","author":"Jentzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B297","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B298","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B299","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B300","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B301","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B302","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B303","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026102519571669700_ehag098-B304","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"2026102519571669700_ehag098-B305","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41591-024-02941-8","article-title":"A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials","volume":"30","author":"Kondo","year":"2024","journal-title":"Nat Med"},{"key":"2026102519571669700_ehag098-B306","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B307","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B308","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B309","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026102519571669700_ehag098-B310","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B311","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.jacc.2024.03.426","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function","volume":"83","author":"Matsumoto","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B312","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B313","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B314","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B315","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Solvd Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B316","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"Consensus Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B317","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Solvd Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B318","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial","volume":"167","author":"Bowling","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026102519571669700_ehag098-B319","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B320","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B321","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/eurjhf\/hft089","article-title":"Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study","volume":"15","author":"Lesogor","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B322","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B323","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B324","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B325","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B326","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B327","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B328","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B329","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B330","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1161\/01.cir.94.11.2800","article-title":"Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group","volume":"94","author":"Colucci","year":"1996","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B331","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B332","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.cardfail.2008.11.003","article-title":"The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR\/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)","volume":"15","author":"Ghali","year":"2009","journal-title":"J Card Fail"},{"key":"2026102519571669700_ehag098-B333","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/eurjhf\/hfp104","article-title":"Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial","volume":"11","author":"Cohen-Solal","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B334","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.cir.0000035653.72855.bf","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B335","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.jacc.2019.09.059","article-title":"Impact of renal impairment on beta-blocker efficacy in patients with heart failure","volume":"74","author":"Kotecha","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B336","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1161\/CIRCHEARTFAILURE.109.932558","article-title":"Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials","volume":"4","author":"Wali","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026102519571669700_ehag098-B337","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B338","doi-asserted-by":"publisher","first-page":"40D","DOI":"10.1016\/0002-9149(90)90475-g","article-title":"Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group","volume":"66","author":"Swedberg","year":"1990","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B339","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003588","article-title":"Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: a meta-analysis of published study data","volume":"10","author":"Beldhuis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026102519571669700_ehag098-B340","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.jchf.2024.03.014","article-title":"Sacubitril\/valsartan in patients with heart failure and deterioration in eGFR to <30\u2005mL\/min\/1.73\u2005m(2)","volume":"12","author":"Chatur","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B341","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/s0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B342","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"Digitalis Investigation Group","year":"1997","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B343","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1097\/01.ASN.0000135121.81744.75","article-title":"Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial","volume":"15","author":"Shlipak","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B344","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2415471","article-title":"Digitoxin in patients with heart failure and reduced ejection fraction","volume":"393","author":"Bavendiek","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B345","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/ejhf.59","article-title":"The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT","volume":"16","author":"Voors","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B346","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B347","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B348","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B349","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"406","author":"Butler","year":"2025","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B350","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(25)01682-4","article-title":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials","volume":"406","author":"Zannad","year":"2025","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B351","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B352","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1161\/CIRCULATIONAHA.106.644013","article-title":"Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate\/hydralazine: consistency across subgroups in the African-American Heart Failure Trial","volume":"115","author":"Taylor","year":"2007","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B353","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B354","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B355","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B356","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B357","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B358","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/s41591-025-03671-1","article-title":"Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency","volume":"31","author":"Anker","year":"2025","journal-title":"Nat Med"},{"key":"2026102519571669700_ehag098-B359","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/ehf2.14310","article-title":"Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis","volume":"10","author":"Salah","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026102519571669700_ehag098-B360","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ejhf.2810","article-title":"Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis","volume":"25","author":"Graham","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B361","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/ejhf.2860","article-title":"Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B362","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00392-023-02207-2","article-title":"Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis","volume":"112","author":"Vukadinovic","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026102519571669700_ehag098-B363","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B364","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B365","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B366","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2215\/CJN.0000000000000223","article-title":"Ferric carboxymaltose in iron-deficient patients with hospitalized heart failure and reduced kidney function","volume":"18","author":"Macdougall","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B367","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/ejhf.3237","article-title":"Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure","volume":"26","author":"Packer","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B368","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B369","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","article-title":"Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure","volume":"85","author":"Kosiborod","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B370","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","article-title":"Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials","volume":"21","author":"Connolly","year":"2000","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B371","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7326\/M17-0120","article-title":"Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: a systematic review and meta-analysis","volume":"167","author":"Kolodziejczak","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B372","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1001\/jama.292.23.2874","article-title":"Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials","volume":"292","author":"Desai","year":"2004","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B373","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/eurheartj\/ehac026","article-title":"Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial","volume":"43","author":"Beohar","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B374","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa2314328","article-title":"Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation","volume":"391","author":"Anker","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B375","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jchf.2014.06.007","article-title":"Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials","volume":"2","author":"Steinberg","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B376","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.ajkd.2013.12.009","article-title":"Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials","volume":"64","author":"Pun","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B377","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2215\/CJN.00750113","article-title":"Cardiac resynchronization therapy in CKD: a systematic review","volume":"8","author":"Garg","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B378","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.hrthm.2010.09.005","article-title":"Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial\u2013Cardiac Resynchronization Therapy (MADIT-CRT)","volume":"7","author":"Goldenberg","year":"2010","journal-title":"Heart Rhythm"},{"key":"2026102519571669700_ehag098-B379","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B380","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B381","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0167-5273(01)00600-3","article-title":"Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials","volume":"82","author":"Faris","year":"2002","journal-title":"Int J Cardiol"},{"key":"2026102519571669700_ehag098-B382","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B383","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1161\/01.res.39.3.358","article-title":"Transcapillary escape rate of albumin and right atrial pressure in chronic congestive heart failure before and after treatment","volume":"39","author":"Hesse","year":"1976","journal-title":"Circ Res"},{"key":"2026102519571669700_ehag098-B384","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1152\/ajplegacy.1975.229.1.93","article-title":"Renal secretion of [35-S]furosemide and depression by albumin binding","volume":"229","author":"Bowman","year":"1975","journal-title":"Am J Physiol"},{"key":"2026102519571669700_ehag098-B385","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1476-5381.1996.tb15755.x","article-title":"The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit","volume":"119","author":"Pichette","year":"1996","journal-title":"Br J Pharmacol"},{"key":"2026102519571669700_ehag098-B386","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B387","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/ejhf.2681","article-title":"Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial","volume":"24","author":"Voors","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B388","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1093\/eurheartj\/ehad557","article-title":"Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial","volume":"44","author":"Meekers","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B389","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/ejhf.2988","article-title":"Combining loop and thiazide diuretics for acute heart failure across the estimated glomerular filtration rate spectrum: a post-hoc analysis of the CLOROTIC trial","volume":"25","author":"Trullas","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B390","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/ejhf.3228","article-title":"Renal function and natriuresis-guided diuretic therapy \u2013 a pre-specified analysis from the PUSH-AHF trial","volume":"26","author":"Damman","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B391","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B392","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B393","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","article-title":"Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function","volume":"5","author":"Metra","year":"2012","journal-title":"Circ Heart Fail"},{"key":"2026102519571669700_ehag098-B394","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic treatment in heart failure","volume":"377","author":"Ellison","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B395","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ejhf.2385","article-title":"Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial","volume":"24","author":"Ter Maaten","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B396","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","article-title":"Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial","volume":"29","author":"Ter Maaten","year":"2023","journal-title":"Nat Med"},{"key":"2026102519571669700_ehag098-B397","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011105","article-title":"Protocolized natriuresis-guided decongestion improves diuretic response: the multicenter ENACT-HF study","volume":"17","author":"Dauw","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026102519571669700_ehag098-B398","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004644","article-title":"Prognostic significance of creatinine increases during an acute heart failure admission in patients with and without residual congestion: a post hoc analysis of the PROTECT data","volume":"11","author":"Metra","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026102519571669700_ehag098-B399","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B400","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B401","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B402","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B403","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B404","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026102519571669700_ehag098-B405","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B406","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial","volume":"44","author":"Trullas","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B407","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.ajkd.2020.04.017","article-title":"Resistant hypertension in people with CKD: a review","volume":"77","author":"Fay","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B408","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100393","article-title":"Milrinone vs dobutamine for the management of cardiogenic shock: implications of renal function and injury","volume":"2","author":"Di Santo","year":"2023","journal-title":"JACC Adv"},{"key":"2026102519571669700_ehag098-B409","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","article-title":"Ultrafiltration in decompensated heart failure with cardiorenal syndrome","volume":"367","author":"Bart","year":"2012","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B410","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614329","article-title":"Single-nephron glomerular filtration rate in healthy adults","volume":"376","author":"Denic","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B411","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B412","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ejhf.2471","article-title":"Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology","volume":"24","author":"Mullens","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026102519571669700_ehag098-B413","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B414","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","article-title":"Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B415","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.jacc.2023.08.026","article-title":"Dapagliflozin in patients with heart failure and deterioration in renal function","volume":"82","author":"Chatur","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B416","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jchf.2020.03.009","article-title":"Acute kidney function declines in the context of decongestion in acute decompensated heart failure","volume":"8","author":"McCallum","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B417","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/MCC.0000000000000746","article-title":"Kidney and liver dysfunction in cardiogenic shock","volume":"26","author":"Lassus","year":"2020","journal-title":"Curr Opin Crit Care"},{"key":"2026102519571669700_ehag098-B418","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJMoa2307227","article-title":"Extracorporeal life support in infarct-related cardiogenic shock","volume":"389","author":"Thiele","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B419","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","article-title":"Microaxial flow pump or standard care in infarct-related cardiogenic shock","volume":"390","author":"Moller","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B420","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006858","article-title":"Comorbid conditions and health-related quality of life in ambulatory heart failure patients: REVIVAL (Registry Evaluation of Vital Information for VADs in Ambulatory Life REVIVAL)","volume":"13","author":"Cascino","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026102519571669700_ehag098-B421","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1161\/CIR.0000000000001273","article-title":"Evaluation and management of kidney dysfunction in advanced heart failure: a scientific statement from the American Heart Association","volume":"150","author":"Tang","year":"2024","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B422","doi-asserted-by":"publisher","first-page":"69","DOI":"10.36628\/ijhf.2020.0030","article-title":"Impact of renal dysfunction on outcomes after left ventricular assist device: a systematic review","volume":"3","author":"Ibrahim","year":"2021","journal-title":"Int J Heart Fail"},{"key":"2026102519571669700_ehag098-B423","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.mayocp.2018.09.021","article-title":"Predictors and outcomes of renal replacement therapy after left ventricular assist device implantation","volume":"94","author":"Asleh","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2026102519571669700_ehag098-B424","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.healun.2017.07.011","article-title":"Pre-operative proteinuria in left ventricular assist devices and clinical outcome","volume":"37","author":"Muslem","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2026102519571669700_ehag098-B425","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.jtcvs.2019.03.098","article-title":"Left ventricular assist device implantation may be feasible in appropriately selected patients with severe renal insufficiency","volume":"159","author":"Pasrija","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026102519571669700_ehag098-B426","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1161\/CIR.0000000000001155","article-title":"Dual-organ transplantation: indications, evaluation, and outcomes for heart-kidney and heart-liver transplantation: a scientific statement from the American Heart Association","volume":"148","author":"Kittleson","year":"2023","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B427","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2022.100707","article-title":"Kidney delayed graft function after combined kidney-solid organ transplantation: a review","volume":"36","author":"Swanson","year":"2022","journal-title":"Transplant Rev"},{"key":"2026102519571669700_ehag098-B428","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jacc.2022.11.053","article-title":"Outcomes of simultaneous heart and kidney transplantation","volume":"81","author":"Itagaki","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B429","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1111\/ajt.16466","article-title":"Need for improvements in simultaneous heart-kidney allocation: the limitation of pretransplant glomerular filtration rate","volume":"21","author":"Shaw","year":"2021","journal-title":"Am J Transplant"},{"key":"2026102519571669700_ehag098-B430","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.amjcard.2020.05.034","article-title":"Characteristics and outcomes of patients undergoing combined organ transplantation (from the United Network for Organ Sharing)","volume":"129","author":"Briasoulis","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B431","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.cardfail.2020.03.002","article-title":"Combined heart-kidney transplant versus sequential kidney transplant in heart transplant recipients","volume":"26","author":"Gallo","year":"2020","journal-title":"J Card Fail"},{"key":"2026102519571669700_ehag098-B432","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMoa1900486","article-title":"A fully magnetically levitated left ventricular assist device \u2013 final report","volume":"380","author":"Mehra","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B433","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1001\/jamainternmed.2017.4831","article-title":"Outcomes associated with left ventricular assist devices among recipients with and without end-stage renal disease","volume":"178","author":"Bansal","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2026102519571669700_ehag098-B434","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.2174\/1381612822666160309115125","article-title":"Atypical chest pain in ACS: a trap especially for women","volume":"22","author":"Ricci","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"Suppl","key":"2026102519571669700_ehag098-B435","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.ijcard.2016.06.221","article-title":"Association between comorbidities and absence of chest pain in acute coronary syndrome with in-hospital outcome","volume":"217","author":"Manfrini","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026102519571669700_ehag098-B436","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jjcc.2010.11.008","article-title":"Atypical presentation of acute coronary syndrome: a significant independent predictor of in-hospital mortality","volume":"57","author":"El-Menyar","year":"2011","journal-title":"J Cardiol"},{"key":"2026102519571669700_ehag098-B437","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1053\/j.ajkd.2005.11.017","article-title":"Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective","volume":"47","author":"Sosnov","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B438","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.jacc.2011.07.010","article-title":"Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease","volume":"58","author":"Go","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B439","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2215\/CJN.03600414","article-title":"Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD","volume":"10","author":"Colbert","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B440","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1161\/CIRCULATIONAHA.117.028901","article-title":"0\/1-Hour triage algorithm for myocardial infarction in patients with renal dysfunction","volume":"137","author":"Twerenbold","year":"2018","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B441","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.3390\/jcm10184216","article-title":"High-sensitivity cardiac troponin T in patients with severe chronic kidney disease and suspected acute coronary syndrome","volume":"10","author":"Alushi","year":"2021","journal-title":"J Clin Med"},{"key":"2026102519571669700_ehag098-B442","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jcmg.2020.05.035","article-title":"Cardiac imaging for coronary heart disease risk stratification in chronic kidney disease","volume":"14","author":"Dilsizian","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026102519571669700_ehag098-B443","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1093\/ndt\/gfi005","article-title":"Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates","volume":"20","author":"Sharma","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B444","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s12350-015-0303-4","article-title":"The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease","volume":"24","author":"Doukky","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"2026102519571669700_ehag098-B445","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/ehjci\/jeu036","article-title":"Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunction","volume":"15","author":"Bhatti","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026102519571669700_ehag098-B446","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2967\/jnumed.111.099325","article-title":"Impaired global myocardial flow dynamics despite normal left ventricular function and regional perfusion in chronic kidney disease: a quantitative analysis of clinical 82Rb PET\/CT studies","volume":"53","author":"Fukushima","year":"2012","journal-title":"J Nucl Med"},{"key":"2026102519571669700_ehag098-B447","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41581-023-00747-4","article-title":"Diagnosis of cardiovascular disease in patients with chronic kidney disease","volume":"19","author":"Zoccali","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"2026102519571669700_ehag098-B448","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008691.pub2","article-title":"Cardiac testing for coronary artery disease in potential kidney transplant recipients","volume":"2011","author":"Wang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B449","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s12350-021-02621-x","article-title":"Diagnostic accuracy of myocardial perfusion imaging in patients evaluated for kidney transplantation: a systematic review and meta-analysis","volume":"29","author":"Kelderman","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"2026102519571669700_ehag098-B450","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12350-020-02449-x","article-title":"Prognostic value of myocardial perfusion imaging in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"29","author":"Cantoni","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"2026102519571669700_ehag098-B451","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jcmg.2012.06.007","article-title":"Coronary vascular dysfunction and prognosis in patients with chronic kidney disease","volume":"5","author":"Murthy","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026102519571669700_ehag098-B452","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.123.015858","article-title":"Comparative effectiveness of PET and SPECT MPI for predicting cardiovascular events after kidney transplant","volume":"17","author":"Huck","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026102519571669700_ehag098-B453","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.119.043916","article-title":"Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in patients with chronic kidney impairment","volume":"141","author":"Bajaj","year":"2020","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B454","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000510402","article-title":"Coronary computed tomography angiography in diagnosing obstructive coronary artery disease in patients with advanced chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Cheng","year":"2021","journal-title":"Cardiorenal Med"},{"key":"2026102519571669700_ehag098-B455","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jcct.2022.03.003","article-title":"Prognostic value of computed tomography derived fractional flow reserve for predicting cardiac events and mortality in kidney transplant candidates","volume":"16","author":"Dahl","year":"2022","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"2026102519571669700_ehag098-B456","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ahj.2021.09.008","article-title":"Predictors of outcome in the ISCHEMIA-CKD trial: anatomy versus ischemia","volume":"243","author":"Bainey","year":"2022","journal-title":"Am Heart J"},{"key":"2026102519571669700_ehag098-B457","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B458","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12882-019-1499-3","article-title":"Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"20","author":"Su","year":"2019","journal-title":"BMC Nephrol"},{"key":"2026102519571669700_ehag098-B459","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists Collaboration","year":"2009","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B460","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B461","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.117.006144","article-title":"Incidence, patterns, and impact of dual antiplatelet therapy cessation among patients with and without chronic kidney disease undergoing percutaneous coronary intervention: results from the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)","volume":"11","author":"Baber","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B462","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B463","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.amjcard.2024.06.003","article-title":"One-month versus three-month dual-antiplatelet therapy in high bleeding risk patients with chronic kidney disease","volume":"225","author":"Mankerious","year":"2024","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B464","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2215\/CJN.12901018","article-title":"Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis","volume":"14","author":"Mavrakanas","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B465","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ahj.2017.11.013","article-title":"Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease","volume":"197","author":"Hwang","year":"2018","journal-title":"Am Heart J"},{"key":"2026102519571669700_ehag098-B466","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B467","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B468","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.jacc.2019.02.048","article-title":"Rivaroxaban plus aspirin in patients with vascular disease and renal dysfunction: from the COMPASS trial","volume":"73","author":"Fox","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B469","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tunon","year":"2020","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B470","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B471","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B472","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"58","author":"Badve","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B473","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1681\/ASN.2014040324","article-title":"Beta-Blocker dialyzability and mortality in older patients receiving hemodialysis","volume":"26","author":"Weir","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B474","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B475","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B476","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/clc.22253","article-title":"Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome","volume":"37","author":"Rhee","year":"2014","journal-title":"Clin Cardiol"},{"key":"2026102519571669700_ehag098-B477","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1053\/euhj.2001.2896","article-title":"Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand","volume":"22","author":"Szwed","year":"2001","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B478","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B479","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease","volume":"382","author":"Maron","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B480","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.amjcard.2009.07.043","article-title":"Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease","volume":"104","author":"Sedlis","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B481","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJMoa1915925","article-title":"Management of coronary disease in patients with advanced kidney disease","volume":"382","author":"Bangalore","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B482","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMoa1916374","article-title":"Health status after invasive or conservative care in coronary and advanced kidney disease","volume":"382","author":"Spertus","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B483","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.kint.2016.03.033","article-title":"Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease","volume":"90","author":"Charytan","year":"2016","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B484","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejim.2017.04.002","article-title":"Comparison of coronary artery bypass grafting and drug-eluting stents in patients with chronic kidney disease and multivessel disease: a meta-analysis","volume":"43","author":"Wang","year":"2017","journal-title":"Eur J Intern Med"},{"key":"2026102519571669700_ehag098-B485","doi-asserted-by":"publisher","DOI":"10.1177\/2040622321990273","article-title":"Coronary artery bypass graft surgery versus stenting for patients with chronic kidney disease and complex coronary artery disease: a systematic review and meta-analysis","volume":"12","author":"Cui","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"2026102519571669700_ehag098-B486","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jacc.2015.06.1334","article-title":"Revascularization in patients with multivessel coronary artery disease and chronic kidney disease: everolimus-eluting stents versus coronary artery bypass graft surgery","volume":"66","author":"Bangalore","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B487","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1161\/CIRCULATIONAHA.105.580084","article-title":"Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database","volume":"113","author":"Cooper","year":"2006","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B488","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1177\/0003319711398864","article-title":"The relationship between chronic kidney disease and SYNTAX score","volume":"62","author":"Coskun","year":"2011","journal-title":"Angiology"},{"key":"2026102519571669700_ehag098-B489","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.amjcard.2007.11.009","article-title":"Impact of renal insufficiency on angiographic, procedural, and in-hospital outcomes following percutaneous coronary intervention","volume":"101","author":"Osten","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B490","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030886","article-title":"Prognostic impact of renal function on 5-year outcomes after fractional flow reserve-guided deferral of revascularization","volume":"12","author":"Itakura","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B491","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.carrev.2016.03.004","article-title":"Impact of vascular access on acute kidney injury after percutaneous coronary intervention","volume":"17","author":"Ando","year":"2016","journal-title":"Cardiovasc Revasc Med"},{"key":"2026102519571669700_ehag098-B492","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.amjcard.2021.07.018","article-title":"Meta-analysis of transradial versus transfemoral access for percutaneous coronary intervention in patients with chronic kidney disease","volume":"157","author":"Latif","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B493","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B494","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40256-020-00447-5","article-title":"Long-term antithrombotic therapy and clinical outcomes in patients with acute coronary syndrome and renal impairment: insights from EPICOR and EPICOR Asia","volume":"21","author":"Huo","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026102519571669700_ehag098-B495","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1365-2796.2009.02204.x","article-title":"Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register","volume":"268","author":"Szummer","year":"2010","journal-title":"J Intern Med"},{"key":"2026102519571669700_ehag098-B496","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00392-012-0461-1","article-title":"Renal dysfunction as a risk factor for painless myocardial infarction: results from Korea Acute Myocardial Infarction Registry","volume":"101","author":"Choi","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"2026102519571669700_ehag098-B497","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ahj.2011.12.002","article-title":"Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System\/National Institutes of Health and the National Registry of Myocardial Infarction","volume":"163","author":"Shroff","year":"2012","journal-title":"Am Heart J"},{"key":"2026102519571669700_ehag098-B498","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B499","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1093\/ndt\/gfr684","article-title":"Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease","volume":"27","author":"Rizk","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B500","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B501","doi-asserted-by":"publisher","author":"Mills","DOI":"10.1093\/eurheartj\/ehag101"},{"key":"2026102519571669700_ehag098-B502","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008032","article-title":"Cardiac troponins for the diagnosis of acute myocardial infarction in chronic kidney disease","volume":"7","author":"Kraus","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B503","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2024.51","article-title":"Cardiac troponins in kidney disease","volume":"20","author":"Murphy","year":"2025","journal-title":"Eur Cardiol"},{"key":"2026102519571669700_ehag098-B504","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae247","article-title":"Kidney function-specific cut-off values of high-sensitivity cardiac troponin T for the diagnosis of acute myocardial infarction","volume":"17","author":"Chen","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026102519571669700_ehag098-B505","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/diagnostics12020276","article-title":"Troponin cut-offs for acute myocardial infarction in patients with impaired renal function\u2014a systematic review and meta-analysis","volume":"12","author":"Kampmann","year":"2022","journal-title":"Diagnostics"},{"key":"2026102519571669700_ehag098-B506","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B507","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ahj.2008.08.019","article-title":"The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial","volume":"157","author":"White","year":"2009","journal-title":"Am Heart J"},{"key":"2026102519571669700_ehag098-B508","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijcard.2009.03.119","article-title":"Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY","volume":"144","author":"Spinler","year":"2010","journal-title":"Int J Cardiol"},{"key":"2026102519571669700_ehag098-B509","doi-asserted-by":"publisher","first-page":"304","DOI":"10.7326\/0003-4819-147-5-200709040-00005","article-title":"Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes","volume":"147","author":"Fox","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B510","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B511","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B512","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B513","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.amjcard.2022.04.040","article-title":"One-year ischemic and bleeding events according to renal function in patients with non-ST-segment elevation acute coronary syndromes treated with percutaneous coronary intervention and third-generation antiplatelet drugs","volume":"176","author":"Ndrepepa","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B514","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/ehjcvp\/pvac016","article-title":"Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD","volume":"8","author":"Dehghani","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026102519571669700_ehag098-B515","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/s0140-6736(24)01616-7","article-title":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials","volume":"404","author":"Valgimigli","year":"2024","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B516","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B517","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41569-023-00901-2","article-title":"De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a consensus statement from an international expert panel on coronary thrombosis","volume":"20","author":"Gorog","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026102519571669700_ehag098-B518","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1093\/eurheartj\/ehab533","article-title":"Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD","volume":"42","author":"Stefanini","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B519","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B520","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B521","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B522","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/s0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B523","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/01.cir.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials","volume":"97","author":"ACE Inhibitor Myocardial Infarction Collaborative Group","year":"1998","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B524","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.jacc.2016.01.050","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction","volume":"67","author":"Evans","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B525","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1001\/archinte.160.17.2645","article-title":"Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function","volume":"160","author":"Frances","year":"2000","journal-title":"Arch Intern Med"},{"key":"2026102519571669700_ehag098-B526","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/S0140-6736(25)01592-2","article-title":"Beta-blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials","volume":"406","author":"Rossello","year":"2025","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B527","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"2026102519571669700_ehag098-B528","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B529","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B530","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1002\/ehf2.15393","article-title":"Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: insights from EMPACT-MI","volume":"12","author":"Fioretti","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026102519571669700_ehag098-B531","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/MCA.0000000000001447","article-title":"Duration of dual antiplatelet treatment after percutaneous coronary intervention in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"36","author":"Apostolos","year":"2025","journal-title":"Coron Artery Dis"},{"key":"2026102519571669700_ehag098-B532","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1197161","article-title":"P2y(12) inhibitor monotherapy after 1-3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials","volume":"10","author":"Yu","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026102519571669700_ehag098-B533","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/eurheartj\/ehac829","article-title":"Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis","volume":"44","author":"Kang","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B534","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC Guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B535","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2004030203","article-title":"Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999","volume":"16","author":"Foley","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B536","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1161\/01.CIR.0000114519.75433.DD","article-title":"High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000","volume":"109","author":"O\u2019Hare","year":"2004","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B537","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1744-9987.2009.00663.x","article-title":"Risk factors of normal ankle-brachial index and low toe-brachial index in hemodialysis patients","volume":"13","author":"Morimoto","year":"2009","journal-title":"Ther Apher Dial"},{"key":"2026102519571669700_ehag098-B538","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003339","article-title":"Ankle brachial index and subsequent cardiovascular disease risk in patients with chronic kidney disease","volume":"5","author":"Chen","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B539","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2018.08.043","article-title":"Chronic kidney disease measures and the risk of abdominal aortic aneurysm","volume":"279","author":"Matsushita","year":"2018","journal-title":"Atherosclerosis"},{"key":"2026102519571669700_ehag098-B540","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.avsg.2013.06.016","article-title":"Risk factors associated with the diagnosis of abdominal aortic aneurysm in patients screened at a regional veterans affairs health care system","volume":"28","author":"Chun","year":"2014","journal-title":"Ann Vasc Surg"},{"key":"2026102519571669700_ehag098-B541","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4174\/astr.2022.103.5.297","article-title":"Chronic kidney disease as a risk factor for abdominal aortic aneurysm: a nationwide population-based study","volume":"103","author":"Jun","year":"2022","journal-title":"Ann Surg Treat Res"},{"key":"2026102519571669700_ehag098-B542","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jvs.2020.08.032","article-title":"Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease","volume":"73","author":"Anantha-Narayanan","year":"2021","journal-title":"J Vasc Surg"},{"key":"2026102519571669700_ehag098-B543","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028622","article-title":"Drug-coated balloon and drug-eluting stent safety in patients with femoropopliteal and severe chronic kidney disease","volume":"12","author":"Hanna","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B544","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ccd.29491","article-title":"Clinical outcomes of patients with and without chronic kidney disease undergoing endovascular revascularization of infrainguinal peripheral artery disease: insights from the XLPAD registry","volume":"98","author":"Kabir","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B545","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jvs.2022.09.003","article-title":"Chronic kidney disease impacts outcomes after abdominal aortic aneurysm repair","volume":"77","author":"Pizano","year":"2023","journal-title":"J Vasc Surg"},{"key":"2026102519571669700_ehag098-B546","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2215\/CJN.05600515","article-title":"CKD and acute and long-term outcome of patients with peripheral artery disease and critical limb ischemia","volume":"11","author":"Luders","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B547","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2020.09.026","article-title":"The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb peripheral arterial disease: a systematic review and meta-analysis","volume":"315","author":"Herraiz-Adillo","year":"2020","journal-title":"Atherosclerosis"},{"key":"2026102519571669700_ehag098-B548","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1358863X16645854","article-title":"A systematic review of the sensitivity and specificity of the toe-brachial index for detecting peripheral artery disease","volume":"21","author":"Tehan","year":"2016","journal-title":"Vasc Med"},{"key":"2026102519571669700_ehag098-B549","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/ndt\/gfv009","article-title":"Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis","volume":"30","author":"Masson","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B550","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1161\/STROKEAHA.120.029680","article-title":"Chronic kidney disease and cerebrovascular disease: consensus and guidance from a KDIGO Controversies Conference","volume":"52","author":"Kelly","year":"2021","journal-title":"Stroke"},{"key":"2026102519571669700_ehag098-B551","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.kint.2019.09.024","article-title":"Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines","volume":"97","author":"Kelly","year":"2020","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B552","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ekir.2023.01.012","article-title":"Association between CKD and major hemorrhage in older persons: data from the Aspirin in Reducing Events in the Elderly randomized trial","volume":"8","author":"Mahady","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026102519571669700_ehag098-B553","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(16)30468-8","article-title":"Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials","volume":"388","author":"Rothwell","year":"2016","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B554","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1161\/STROKEAHA.116.014761","article-title":"Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events)","volume":"47","author":"Zhou","year":"2016","journal-title":"Stroke"},{"key":"2026102519571669700_ehag098-B555","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/23969873221100032","article-title":"European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack","volume":"7","author":"Dawson","year":"2022","journal-title":"Eur Stroke J"},{"key":"2026102519571669700_ehag098-B556","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/ndt\/gfx267","article-title":"Impact of achieved blood pressure on renal function decline and first stroke in hypertensive patients with chronic kidney disease","volume":"33","author":"Li","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B557","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1681\/ASN.2007020256","article-title":"Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study","volume":"18","author":"Perkovic","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B558","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejvs.2009.09.024","article-title":"Carotid plaque composition in chronic kidney disease: a retrospective analysis of patients undergoing carotid endarterectomy","volume":"39","author":"Pelisek","year":"2010","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026102519571669700_ehag098-B559","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1681\/ASN.2009030287","article-title":"Carotid endarterectomy benefits patients with CKD and symptomatic high-grade stenosis","volume":"21","author":"Mathew","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B560","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jvs.2024.04.045","article-title":"Carotid endarterectomy and transcarotid artery revascularization can be performed with acceptable morbidity and mortality in patients with chronic kidney disease","volume":"80","author":"Elizaga","year":"2024","journal-title":"J Vasc Surg"},{"key":"2026102519571669700_ehag098-B561","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.avsg.2023.08.031","article-title":"Carotid endarterectomy should not be recommended to end-stage kidney disease patients with asymptomatic carotid artery disease","volume":"101","author":"Hafeez","year":"2024","journal-title":"Ann Vasc Surg"},{"key":"2026102519571669700_ehag098-B562","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamasurg.2016.1504","article-title":"Perioperative and long-term outcomes after carotid endarterectomy in hemodialysis patients","volume":"151","author":"Cooper","year":"2016","journal-title":"JAMA Surg"},{"key":"2026102519571669700_ehag098-B563","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.jvs.2024.06.008","article-title":"Outcomes of carotid revascularization stratified by procedure in patients with an estimated glomerular filtration rate of <30 and dialysis patients","volume":"80","author":"Caron","year":"2024","journal-title":"J Vasc Surg"},{"key":"2026102519571669700_ehag098-B564","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"},{"key":"2026102519571669700_ehag098-B565","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1161\/STROKEAHA.122.039086","article-title":"Alteplase for stroke with unknown onset time in chronic kidney disease: a pooled analysis of individual participant data","volume":"53","author":"Miwa","year":"2022","journal-title":"Stroke"},{"key":"2026102519571669700_ehag098-B566","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ndt\/gfab197","article-title":"Epidemiology, thrombolytic management, and outcomes of acute stroke among patients with chronic kidney disease: a systematic review and meta-analysis","volume":"37","author":"Zamberg","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B567","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1212\/WNL.0000000000009756","article-title":"Intravenous thrombolysis in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"95","author":"Malhotra","year":"2020","journal-title":"Neurology"},{"key":"2026102519571669700_ehag098-B568","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/STROKEAHA.117.017808","article-title":"Influence of renal impairment on outcome for thrombolysis-treated acute ischemic stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) post hoc analysis","volume":"48","author":"Carr","year":"2017","journal-title":"Stroke"},{"key":"2026102519571669700_ehag098-B569","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1177\/23969873231224200","article-title":"Kidney dysfunction predicts 90 days mortality after stroke thrombectomy independent of cardiovascular risk factors and chronic kidney disease","volume":"9","author":"Heinze","year":"2024","journal-title":"Eur Stroke J"},{"key":"2026102519571669700_ehag098-B570","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13123469","article-title":"Chronic kidney disease increases mortality and reduces the chance of a favorable outcome in stroke patients treated with mechanical thrombectomy\u2014single-center study","volume":"13","author":"Boronczyk","year":"2024","journal-title":"J Clin Med"},{"key":"2026102519571669700_ehag098-B571","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000536493","article-title":"Acute and chronic kidney dysfunction and prognosis following thrombectomy for ischemic stroke","volume":"55","author":"Bobot","year":"2024","journal-title":"Am J Nephrol"},{"key":"2026102519571669700_ehag098-B572","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1177\/17474930211045805","article-title":"Effect of renal impairment on the efficacy and safety of intra-arterial treatment: a post-hoc analysis of DIRECT-MT study","volume":"17","author":"Hu","year":"2022","journal-title":"Int J Stroke"},{"key":"2026102519571669700_ehag098-B573","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ekir.2018.04.011","article-title":"Inequality in care and differences in outcome following stroke in people with ESRD","volume":"3","author":"Findlay","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2026102519571669700_ehag098-B574","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.ajkd.2008.05.004","article-title":"Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study","volume":"52","author":"Kurella Tamura","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B575","doi-asserted-by":"publisher","first-page":"e711\u2013","DOI":"10.1212\/WNL.0000000000013205","article-title":"Associations of chronic kidney disease with dementia before and after TIA and stroke: population-based cohort study","volume":"98","author":"Kelly","year":"2022","journal-title":"Neurology"},{"key":"2026102519571669700_ehag098-B576","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12882-020-01764-2","article-title":"Patterns and characteristics of cognitive functioning in older patients approaching end stage kidney disease, the COPE-study","volume":"21","author":"van Deudekom","year":"2020","journal-title":"BMC Nephrol"},{"key":"2026102519571669700_ehag098-B577","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1159\/000452603","article-title":"Cognitive impairment and structural neuroimaging abnormalities among patients with chronic kidney disease","volume":"41","author":"Pi","year":"2016","journal-title":"Kidney Blood Press Res"},{"key":"2026102519571669700_ehag098-B578","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1053\/j.ajkd.2023.12.022","article-title":"Changes in cognitive function after kidney transplantation: a longitudinal cohort study","volume":"84","author":"Gupta","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B579","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1681\/ASN.2018070726","article-title":"Frailty and changes in cognitive function after kidney transplantation","volume":"30","author":"Chu","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B580","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1681\/ASN.2013101086","article-title":"Randomized clinical trial of dialysate cooling and effects on brain white matter","volume":"26","author":"Eldehni","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B581","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1681\/ASN.2020050584","article-title":"Normalization of cerebral blood flow, neurochemicals, and white matter integrity after kidney transplantation","volume":"32","author":"Lepping","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B582","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial","volume":"321","author":"Sprint Mind Investigators for the SPRINT Research Group","year":"2019","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B583","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/archinternmed.2010.502","article-title":"Albuminuria and decline in cognitive function: the ONTARGET\/TRANSCEND studies","volume":"171","author":"Barzilay","year":"2011","journal-title":"Arch Intern Med"},{"key":"2026102519571669700_ehag098-B584","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008834.pub4","article-title":"Antiplatelet agents for chronic kidney disease","volume":"2","author":"Natale","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B585","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013098","article-title":"Effect of baseline kidney function on the risk of recurrent stroke and on effects of intensive blood pressure control in patients with previous lacunar stroke: a post hoc analysis of the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes)","volume":"8","author":"Agarwal","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B586","doi-asserted-by":"publisher","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B587","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ejvs.2023.01.020","article-title":"Optimal management of asymptomatic carotid artery stenosis: a systematic review and network meta-analysis","volume":"65","author":"Gasior","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026102519571669700_ehag098-B588","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(07)60194-9","article-title":"Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis","volume":"369","author":"Phrommintikul","year":"2007","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B589","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","article-title":"Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease","volume":"153","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B590","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials","volume":"384","author":"Emberson","year":"2014","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B591","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials","volume":"387","author":"Goyal","year":"2016","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B592","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/bmj.314.7088.1151","article-title":"Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. Stroke Unit Trialists\u2019 Collaboration","volume":"314","year":"1997","journal-title":"BMJ"},{"key":"2026102519571669700_ehag098-B593","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/jth.12652","article-title":"Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"12","author":"Christiansen","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2026102519571669700_ehag098-B594","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B595","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.22886","article-title":"Assessment of outcomes among patients with venous thromboembolism with and without chronic kidney disease","volume":"3","author":"Goto","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026102519571669700_ehag098-B596","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000523777","article-title":"Venous thromboembolism in kidney diseases and genetic predisposition","volume":"8","author":"Wu","year":"2022","journal-title":"Kidney Dis"},{"key":"2026102519571669700_ehag098-B597","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/eurheartj\/ehz726","article-title":"The 2019 ESC Guidelines on the diagnosis and management of acute pulmonary embolism","volume":"40","author":"Konstantinides","year":"2019","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B598","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/eurjpc\/zwab088","article-title":"Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function","volume":"29","author":"Mazzolai","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519571669700_ehag098-B599","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.thromres.2020.11.036","article-title":"Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: a systematic review and meta-analysis","volume":"198","author":"Alhousani","year":"2021","journal-title":"Thromb Res"},{"key":"2026102519571669700_ehag098-B600","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B601","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1160\/TH17-03-0176","article-title":"Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II","volume":"117","author":"Goldhaber","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026102519571669700_ehag098-B602","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai","year":"2013","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B603","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-9560-12-25","article-title":"Rivaroxaban versus enoxaparin\/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment","volume":"12","author":"Bauersachs","year":"2014","journal-title":"Thromb J"},{"key":"2026102519571669700_ehag098-B604","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B605","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1055\/s-0041-1740254","article-title":"Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease","volume":"122","author":"Cohen","year":"2022","journal-title":"Thromb Haemost"},{"key":"2026102519571669700_ehag098-B606","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamadermatol.2016.4821","article-title":"Warfarin-associated nonuremic calciphylaxis","volume":"153","author":"Yu","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2026102519571669700_ehag098-B607","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B608","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/j.ajkd.2015.01.022","article-title":"Dose-finding study of rivaroxaban in hemodialysis patients","volume":"66","author":"De Vriese","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B609","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.thromres.2023.06.027","article-title":"Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: a systematic review and meta-analysis","volume":"229","author":"Almajdi","year":"2023","journal-title":"Thromb Res"},{"key":"2026102519571669700_ehag098-B610","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2215\/CJN.14021021","article-title":"Apixaban versus warfarin for treatment of venous thromboembolism in patients receiving long-term dialysis","volume":"17","author":"Wetmore","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B611","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B612","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B613","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000501095","article-title":"Percent consonant correct as an outcome measure for cleft speech in an intervention study","volume":"72","author":"Sell","year":"2020","journal-title":"Folia Phoniatr Logop"},{"key":"2026102519571669700_ehag098-B614","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.ajkd.2023.07.023","article-title":"Kidney function, albuminuria, and risk of incident atrial fibrillation: a systematic review and meta-analysis","volume":"83","author":"Ha","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B615","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1093\/ndt\/gfs416","article-title":"Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis","volume":"27","author":"Zimmerman","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B616","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.2215\/CJN.04060318","article-title":"Incident atrial fibrillation and the risk of stroke in adults with chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project","volume":"13","author":"Carrero","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B617","doi-asserted-by":"publisher","DOI":"10.1177\/2054358119892372","article-title":"The risk of stroke and stroke type in patients with atrial fibrillation and chronic kidney disease","volume":"6","author":"Mace-Brickman","year":"2019","journal-title":"Can J Kidney Health Dis"},{"key":"2026102519571669700_ehag098-B618","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jclinepi.2020.03.015","article-title":"A systematic review and external validation of stroke prediction models demonstrates poor performance in dialysis patients","volume":"123","author":"de Jong","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2026102519571669700_ehag098-B619","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/eurheartj\/ehab059","article-title":"Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function","volume":"42","author":"de Jong","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B620","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2215\/CJN.01060121","article-title":"Prediction of incident atrial fibrillation in chronic kidney disease: the Chronic Renal Insufficiency Cohort study","volume":"16","author":"Zelnick","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B621","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1253\/circj.CJ-18-0218","article-title":"Validation of conventional thromboembolic risk factors in a Korean atrial fibrillation population\u2014suggestion for a novel scoring system, CHA2DS2-VAK","volume":"82","author":"Cha","year":"2018","journal-title":"Circ J"},{"key":"2026102519571669700_ehag098-B622","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/eurheartj\/ehu139","article-title":"Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study","volume":"36","author":"Friberg","year":"2015","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B623","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","article-title":"Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts","volume":"127","author":"Piccini","year":"2013","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B624","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.jacc.2013.02.035","article-title":"Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project","volume":"61","author":"Banerjee","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B625","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cjca.2016.08.018","article-title":"Are existing risk scores for nonvalvular atrial fibrillation useful for prediction or risk adjustment in patients with chronic kidney disease?","volume":"33","author":"McAlister","year":"2017","journal-title":"Can J Cardiol"},{"key":"2026102519571669700_ehag098-B626","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/ndt\/gfy387","article-title":"Performance of bleeding risk scores in dialysis patients","volume":"34","author":"Ocak","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B627","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008928","article-title":"Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from ORBIT-AF","volume":"7","author":"Washam","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B628","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.avsg.2020.03.037","article-title":"Role of frailty and comorbidity status in predicting morbidity and mortality in patients with acute mesenteric ischemia","volume":"67","author":"Chen","year":"2020","journal-title":"Ann Vasc Surg"},{"key":"2026102519571669700_ehag098-B629","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B630","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/j.ajkd.2021.02.328","article-title":"Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis","volume":"78","author":"Su","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B631","doi-asserted-by":"publisher","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis","volume":"171","author":"Ha","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B632","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B633","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B634","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.34067\/KID.0000000809","article-title":"Safety and effectiveness of apixaban versus warfarin by kidney function in atrial fibrillation: a binational population-based study","volume":"6","author":"Lam","year":"2025","journal-title":"Kidney360"},{"key":"2026102519571669700_ehag098-B635","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1378\/chest.15-1719","article-title":"Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies","volume":"149","author":"Dahal","year":"2016","journal-title":"Chest"},{"key":"2026102519571669700_ehag098-B636","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cjca.2017.02.004","article-title":"Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis","volume":"33","author":"Harel","year":"2017","journal-title":"Can J Cardiol"},{"key":"2026102519571669700_ehag098-B637","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004925","article-title":"Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction","volume":"6","author":"Szummer","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B638","doi-asserted-by":"publisher","first-page":"635.e1","DOI":"10.1016\/j.amjmed.2015.11.032","article-title":"Warfarin and vascular calcification","volume":"129","author":"Poterucha","year":"2016","journal-title":"Am J Med"},{"key":"2026102519571669700_ehag098-B639","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B640","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1681\/ASN.0000000000000495","article-title":"Anticoagulation for patients with atrial fibrillation receiving dialysis: a pilot randomized controlled trial","volume":"36","author":"Harel","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B641","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034176","article-title":"Anticoagulation for patients with concomitant atrial fibrillation and end-stage renal disease: a systematic review and network meta-analysis","volume":"13","author":"Kao","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B642","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B643","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B644","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.amjcard.2020.12.081","article-title":"Effect of glomerular filtration rates on outcomes following percutaneous left atrial appendage closure","volume":"145","author":"Faroux","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B645","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.jcin.2021.06.008","article-title":"The Association of Chronic Kidney Disease with outcomes following percutaneous left atrial appendage closure","volume":"14","author":"Ahuja","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B646","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/pace.14537","article-title":"Left atrial appendage closure using WATCHMAN device in chronic kidney disease and end-stage renal disease patients","volume":"45","author":"Jamal","year":"2022","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026102519571669700_ehag098-B647","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287928","article-title":"Efficacy and safety of patients with chronic kidney disease undergoing left atrial appendage closure for atrial fibrillation","volume":"18","author":"Liu","year":"2023","journal-title":"PLoS One"},{"key":"2026102519571669700_ehag098-B648","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae035","article-title":"Practical guide on left atrial appendage closure for the non-implanting physician: an international consensus paper","volume":"26","author":"Potpara","year":"2024","journal-title":"Europace"},{"key":"2026102519571669700_ehag098-B649","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12928-023-00972-5","article-title":"Feasibility of contrast-free left atrial appendage closure with WATCHMAN FLX device for patients with chronic kidney disease","volume":"39","author":"Okada","year":"2024","journal-title":"Cardiovasc Interv Ther"},{"key":"2026102519571669700_ehag098-B650","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B651","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B652","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1056\/NEJMoa0708789","article-title":"Rhythm control versus rate control for atrial fibrillation and heart failure","volume":"358","author":"Roy","year":"2008","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B653","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1067\/mhj.2002.122875","article-title":"Baseline characteristics of patients with atrial fibrillation: the AFFIRM study","volume":"143","year":"2002","journal-title":"Am Heart J"},{"key":"2026102519571669700_ehag098-B654","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B655","doi-asserted-by":"publisher","first-page":"439","DOI":"10.5603\/CJ.2013.0104","article-title":"Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III trial","volume":"20","author":"Williams","year":"2013","journal-title":"Cardiol J"},{"key":"2026102519571669700_ehag098-B656","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ahj.2013.05.010","article-title":"Management of atrial fibrillation in chronic kidney disease: double trouble","volume":"166","author":"Nimmo","year":"2013","journal-title":"Am Heart J"},{"key":"2026102519571669700_ehag098-B657","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/00045391-199704000-00004","article-title":"Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure","volume":"4","author":"Napoli","year":"1997","journal-title":"Am J Ther"},{"key":"2026102519571669700_ehag098-B658","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/ehjcvp\/pvab090","article-title":"Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial","volume":"8","author":"Vamos","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026102519571669700_ehag098-B659","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ki.2014.195","article-title":"Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease","volume":"87","author":"Reinecke","year":"2015","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B660","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1540-8167.2011.02069.x","article-title":"Renal dysfunction and atrial fibrillation recurrence following cardioversion","volume":"22","author":"Schmidt","year":"2011","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026102519571669700_ehag098-B661","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.amjcard.2009.09.037","article-title":"Relation of recurrence of atrial fibrillation after successful cardioversion to renal function","volume":"105","author":"Schmidt","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B662","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5603\/CJ.a2013.0116","article-title":"Systematic review and meta-analysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation","volume":"21","author":"Li","year":"2014","journal-title":"Cardiol J"},{"key":"2026102519571669700_ehag098-B663","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.acvd.2019.02.006","article-title":"Renal function and outcomes after catheter ablation of patients with atrial fibrillation: the Guangzhou atrial fibrillation ablation registry","volume":"112","author":"Deng","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"2026102519571669700_ehag098-B664","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/jce.15354","article-title":"Temporal trends and in-hospital complications of catheter ablation for atrial fibrillation among patients with moderate and advanced chronic kidney diseases: 2005-2018","volume":"33","author":"Prasitlumkum","year":"2022","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026102519571669700_ehag098-B665","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/europace\/eut230","article-title":"The impact of haemodialysis on the outcomes of catheter ablation in patients with paroxysmal atrial fibrillation","volume":"16","author":"Takigawa","year":"2014","journal-title":"Europace"},{"key":"2026102519571669700_ehag098-B666","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1540-8167.2012.02422.x","article-title":"Outcomes of ablation of paroxysmal atrial fibrillation in patients on chronic hemodialysis","volume":"23","author":"Sairaku","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026102519571669700_ehag098-B667","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ndt\/gft233","article-title":"Efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in chronic hemodialysis patients","volume":"29","author":"Hayashi","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B668","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2016.04.007","article-title":"Atrial fibrillation in chronic kidney disease","volume":"33","author":"Voroneanu","year":"2016","journal-title":"Eur J Intern Med"},{"key":"2026102519571669700_ehag098-B669","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jjcc.2020.07.002","article-title":"Improvement in renal and endothelial function after catheter ablation in patients with persistent atrial fibrillation","volume":"76","author":"Okawa","year":"2020","journal-title":"J Cardiol"},{"key":"2026102519571669700_ehag098-B670","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jce.12530","article-title":"Improvement in estimated glomerular filtration rate in patients with chronic kidney disease undergoing catheter ablation for atrial fibrillation","volume":"26","author":"Navaravong","year":"2015","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026102519571669700_ehag098-B671","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/jcdd10040151","article-title":"Long-term renal function after catheter ablation of atrial fibrillation","volume":"10","author":"Kovacevic","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026102519571669700_ehag098-B672","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/jce.14979","article-title":"Safety and complications of catheter ablation for atrial fibrillation: predictors of complications from an updated analysis the National Inpatient Database","volume":"32","author":"Wu","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026102519571669700_ehag098-B673","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/jce.13118","article-title":"Safety and clinical outcomes of catheter ablation of atrial fibrillation in patients with chronic kidney disease","volume":"28","author":"Ullal","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026102519571669700_ehag098-B674","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/s0140-6736(00)03230-x","article-title":"Rhythm or rate control in atrial fibrillation\u2013Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial","volume":"356","author":"Hohnloser","year":"2000","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B675","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ki.2009.219","article-title":"Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease","volume":"76","author":"Pun","year":"2009","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B676","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2215\/cjn.01130307","article-title":"Can we prevent sudden cardiac death in dialysis patients?","volume":"2","author":"Herzog","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B677","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B678","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B679","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1161\/CIRCULATIONAHA.119.039818","article-title":"Prophylactic use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients","volume":"139","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B680","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1053\/j.ajkd.2013.03.035","article-title":"Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"62","author":"Tentori","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B681","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1056\/NEJMoa1901111","article-title":"Antibacterial envelope to prevent cardiac implantable device infection","volume":"380","author":"Tarakji","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B682","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/europace\/euab139","article-title":"Infections of cardiac implantable electronic devices: still a cause of high mortality","volume":"23","author":"Goette","year":"2021","journal-title":"Europace"},{"key":"2026102519571669700_ehag098-B683","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.hrthm.2024.02.054","article-title":"Effects of envelopes on cardiac implantable electronic device pocket healing: a head-to-head preclinical evaluation","volume":"21","author":"Virmani","year":"2024","journal-title":"Heart Rhythm"},{"key":"2026102519571669700_ehag098-B684","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2217\/cer-2017-0080","article-title":"Incidence and costs of cardiac device infections: retrospective analysis using German health claims data","volume":"7","author":"Ludwig","year":"2018","journal-title":"J Comp Eff Res"},{"key":"2026102519571669700_ehag098-B685","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.123.012446","article-title":"The BLISTER Score: a novel, externally validated tool for predicting cardiac implantable electronic device infections, and its cost-utility implications for antimicrobial envelope use","volume":"17","author":"Maclean","year":"2024","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026102519571669700_ehag098-B686","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/europace\/euab028","article-title":"Use of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac implantable electronic device infection risk score","volume":"23","author":"Ahmed","year":"2021","journal-title":"Europace"},{"key":"2026102519571669700_ehag098-B687","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/eurheartj\/ehaa010","article-title":"European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections\u2013endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"41","author":"Blomstrom-Lundqvist","year":"2020","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B688","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae169","article-title":"Chronic kidney disease and transvenous cardiac implantable electronic device infection\u2014is there an impact on healthcare utilization, costs, disease progression, and mortality?","volume":"26","author":"Wright","year":"2024","journal-title":"Europace"},{"key":"2026102519571669700_ehag098-B689","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1525-139X.2012.01053.x","article-title":"Transvenous cardiac implantable electronic devices and hemodialysis catheters: recommendations to curtail a potentially lethal combination","volume":"25","author":"Asif","year":"2012","journal-title":"Semin Dial"},{"key":"2026102519571669700_ehag098-B690","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2215\/CJN.07920520","article-title":"Trends in use and in-hospital outcomes of subcutaneous implantable cardioverter defibrillators in patients undergoing long-term dialysis","volume":"15","author":"Pun","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B691","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10840-024-01767-1","article-title":"Subcutaneous cardioverter defibrillator implanted intermuscularly in patients with end-stage renal disease requiring hemodialysis: 5-year follow-up","volume":"68","author":"Kloppe","year":"2025","journal-title":"J Interv Card Electrophysiol"},{"key":"2026102519571669700_ehag098-B692","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.hrthm.2020.04.036","article-title":"Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: results from the S-ICD post-approval study","volume":"17","author":"El-Chami","year":"2020","journal-title":"Heart Rhythm"},{"key":"2026102519571669700_ehag098-B693","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab513","article-title":"Impact of choice of prophylaxis on the microbiology of cardiac implantable electronic device infections: insights from the Prevention of Arrhythmia Device Infection Trial (PADIT)","volume":"8","author":"Longtin","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026102519571669700_ehag098-B694","doi-asserted-by":"publisher","first-page":"iv3\u2013","DOI":"10.1093\/europace\/euab042","article-title":"Epidemiology of cardiac implantable electronic device infections: incidence and risk factors","volume":"23","author":"Han","year":"2021","journal-title":"Europace"},{"key":"2026102519571669700_ehag098-B695","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1397138","article-title":"Comparison of infection and complication rates associated with transvenous vs. subcutaneous defibrillators in patients with stage 4 chronic kidney disease: a multicenter long-term retrospective follow-up","volume":"11","author":"Schiedat","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2026102519571669700_ehag098-B696","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jacc.2018.10.068","article-title":"Kidney dysfunction and the risk of developing aortic stenosis","volume":"73","author":"Vavilis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B697","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006044","article-title":"Prevalence and outcomes of left-sided valvular heart disease associated with chronic kidney disease","volume":"6","author":"Samad","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B698","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.ajkd.2007.05.020","article-title":"Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"50","author":"Ix","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B699","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.amjcard.2016.03.048","article-title":"Effect of end-stage renal disease on rate of progression of aortic stenosis","volume":"117","author":"Kim","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B700","doi-asserted-by":"publisher","first-page":"c40","DOI":"10.1159\/000071280","article-title":"Accelerated progression of calcific aortic stenosis in dialysis patients","volume":"94","author":"Perkovic","year":"2003","journal-title":"Nephron Clin Pract"},{"key":"2026102519571669700_ehag098-B701","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1093\/ndt\/gfad116","article-title":"Chronic kidney disease is a key risk factor for aortic stenosis progression","volume":"38","author":"Candellier","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B702","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017190","article-title":"Severe aortic stenosis and chronic kidney disease: outcomes and impact of aortic valve replacement","volume":"9","author":"Bohbot","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B703","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B704","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Evolve Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B705","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.121.053708","article-title":"Effect of denosumab or alendronic acid on the progression of aortic stenosis: a double-blind randomized controlled trial","volume":"143","author":"Pawade","year":"2021","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B706","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B707","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B708","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1093\/eurheartj\/ehaf194","article-title":"2025 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"46","author":"Praz","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B709","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.athoracsur.2011.02.015","article-title":"Impact of preoperative renal dysfunction on long-term survival for patients undergoing aortic valve replacement","volume":"91","author":"Thourani","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"2026102519571669700_ehag098-B710","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1093\/eurheartj\/ehu175","article-title":"Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients","volume":"35","author":"Allende","year":"2014","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B711","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.amjcard.2022.01.048","article-title":"Effect of chronic kidney disease on 5-year outcome in patients with heart failure and secondary mitral regurgitation undergoing percutaneous mitraclip insertion","volume":"171","author":"Sisinni","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B712","doi-asserted-by":"publisher","first-page":"734\u201344","DOI":"10.1093\/ejcts\/ezs043","article-title":"EuroSCORE II","volume":"41","author":"Nashef","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026102519571669700_ehag098-B713","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.athoracsur.2009.05.056","article-title":"The Society of Thoracic Surgeons 2008 cardiac surgery risk models: Part 2\u2013Isolated valve surgery","volume":"88","author":"O\u2019Brien","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"2026102519571669700_ehag098-B714","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.amjcard.2023.10.014","article-title":"Impact on kidney function and medium-term outcomes of transcatheter aortic valve replacement in patients with chronic kidney disease","volume":"210","author":"Naser","year":"2024","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B715","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jacc.2021.02.014","article-title":"Infective endocarditis in patients on chronic hemodialysis","volume":"77","author":"Pericas","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B716","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.jcin.2021.07.004","article-title":"5-Year outcomes comparing surgical versus transcatheter aortic valve replacement in patients with chronic kidney disease","volume":"14","author":"Garcia","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B717","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/ccd.27928","article-title":"Clinical impact of baseline chronic kidney disease in patients undergoing transcatheter or surgical aortic valve replacement","volume":"93","author":"Pineda","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B718","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2400685","article-title":"Transcatheter or surgical treatment of aortic-valve stenosis","volume":"390","author":"Blankenberg","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B719","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.kint.2021.06.028","article-title":"Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"100","author":"Lameire","year":"2021","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B720","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1681\/ASN.2016010105","article-title":"AKI and long-term risk for cardiovascular events and mortality","volume":"28","author":"Odutayo","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B721","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eclinm.2018.10.007","article-title":"Prophylactic intravenous hydration to protect renal function from intravascular iodinated contrast material (AMACING): long-term results of a prospective, randomised, controlled trial","volume":"4-5","author":"Nijssen","year":"2018","journal-title":"EClinicalMedicine"},{"key":"2026102519571669700_ehag098-B722","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/ccd.29387","article-title":"Meta-analysis of intravascular volume expansion strategies to prevent contrast-associated acute kidney injury following invasive angiography","volume":"98","author":"Michel","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B723","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/ajt.13545","article-title":"Repeated contrast administration is associated with low risk of postcontrast acute kidney injury and long-term complications in patients with severe chronic kidney disease","volume":"16","author":"Winther","year":"2016","journal-title":"Am J Transplant"},{"key":"2026102519571669700_ehag098-B724","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.xkme.2020.01.001","article-title":"Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation","volume":"2","author":"Davenport","year":"2020","journal-title":"Kidney Med"},{"key":"2026102519571669700_ehag098-B725","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMclde2204693","article-title":"Avoiding contrast-enhanced imaging to prevent contrast-induced acute kidney injury","volume":"387","author":"Lee","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B726","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(21)02326-6","article-title":"A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry","volume":"398","author":"Mehran","year":"2021","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B727","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jcin.2021.11.026","article-title":"Long-term clinical impact of contrast-associated acute kidney injury following PCI: an ADAPT-DES substudy","volume":"15","author":"Mohebi","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B728","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcin.2013.06.016","article-title":"Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry","volume":"7","author":"Tsai","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B729","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1161\/CIRCULATIONAHA.106.671644","article-title":"Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease","volume":"115","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B730","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jcin.2014.05.024","article-title":"Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial","volume":"7","author":"Mariani","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B731","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1148\/radiology.188.1.8511292","article-title":"Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media","volume":"188","author":"Barrett","year":"1993","journal-title":"Radiology"},{"key":"2026102519571669700_ehag098-B732","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.amjcard.2013.08.040","article-title":"Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy","volume":"113","author":"Minsinger","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B733","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijcard.2016.11.170","article-title":"Contrast media use in patients with chronic kidney disease undergoing coronary angiography: a systematic review and meta-analysis of randomized trials","volume":"228","author":"Pandya","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026102519571669700_ehag098-B734","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M15-1402","article-title":"Comparative effect of contrast media type on the incidence of contrast-induced nephropathy: a systematic review and meta-analysis","volume":"164","author":"Eng","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B735","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jcin.2009.05.002","article-title":"The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials","volume":"2","author":"Reed","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B736","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2006.02.073","article-title":"A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media","volume":"48","author":"McCullough","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B737","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jacc.2006.06.047","article-title":"Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial","volume":"48","author":"Jo","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B738","doi-asserted-by":"publisher","first-page":"176","DOI":"10.25270\/jic\/18.00331","article-title":"Ultra-low contrast percutaneous coronary intervention to minimize the risk for contrast-induced acute kidney injury in patients with severe chronic kidney disease","volume":"31","author":"Azzalini","year":"2019","journal-title":"J Invasive Cardiol"},{"key":"2026102519571669700_ehag098-B739","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/CIRCINTERVENTIONS.114.001545","article-title":"Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention","volume":"7","author":"Ando","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B740","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7326\/0003-4819-150-3-200902030-00006","article-title":"Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality","volume":"150","author":"Marenzi","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B741","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jacc.2007.03.058","article-title":"Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention","volume":"50","author":"Laskey","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"2026102519571669700_ehag098-B742","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1016\/j.jacc.2017.02.070","article-title":"Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX","volume":"69","author":"Ando","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B743","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamainternmed.2019.7428","article-title":"Effect of no prehydration vs sodium bicarbonate prehydration prior to contrast-enhanced computed tomography in the prevention of postcontrast acute kidney injury in adults with chronic kidney disease: the Kompas Randomized Clinical Trial","volume":"180","author":"Timal","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026102519571669700_ehag098-B744","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0140-6736(17)30057-0","article-title":"Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial","volume":"389","author":"Nijssen","year":"2017","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B745","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1710933","article-title":"Outcomes after angiography with sodium bicarbonate and acetylcysteine","volume":"378","author":"Weisbord","year":"2018","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B746","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189372","article-title":"Randomized trial of one-hour sodium bicarbonate vs standard periprocedural saline hydration in chronic kidney disease patients undergoing cardiovascular contrast procedures","volume":"13","author":"Kooiman","year":"2018","journal-title":"PLoS One"},{"key":"2026102519571669700_ehag098-B747","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/ndt\/gfu025","article-title":"A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography","volume":"29","author":"Kooiman","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B748","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jama.300.9.1038","article-title":"Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial","volume":"300","author":"Brar","year":"2008","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B749","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jcin.2023.03.025","article-title":"Simplified rapid hydration prevents contrast-associated acute kidney injury among CKD patients undergoing coronary angiography","volume":"16","author":"Liu","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B750","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/MCA.0000000000000607","article-title":"Effectiveness of oral hydration in preventing contrast-induced acute kidney injury in patients undergoing coronary angiography or intervention: a pairwise and network meta-analysis","volume":"29","author":"Zhang","year":"2018","journal-title":"Coron Artery Dis"},{"key":"2026102519571669700_ehag098-B751","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/archinte.162.3.329","article-title":"Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty","volume":"162","author":"Mueller","year":"2002","journal-title":"Arch Intern Med"},{"key":"2026102519571669700_ehag098-B752","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002715","article-title":"How strong is the evidence for sodium bicarbonate to prevent contrast-induced acute kidney injury after coronary angiography and percutaneous coronary intervention?","volume":"95","author":"Dong","year":"2016","journal-title":"Medicine"},{"key":"2026102519571669700_ehag098-B753","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1161\/CIRCINTERVENTIONS.113.000653","article-title":"Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial","volume":"7","author":"Thayssen","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B754","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1161\/CIRCINTERVENTIONS.111.961391","article-title":"Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial","volume":"4","author":"Maioli","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B755","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO Clinical Practice Guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2026102519571669700_ehag098-B756","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.116.004383","article-title":"Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical Bayesian network meta-analysis of 124 trials and 28\u00a0240 patients","volume":"10","author":"Giacoppo","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B757","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.amjmed.2011.06.029","article-title":"Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review","volume":"125","author":"Cruz","year":"2012","journal-title":"Am J Med"},{"key":"2026102519571669700_ehag098-B758","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjmed.2005.08.002","article-title":"Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients","volume":"119","author":"Marenzi","year":"2006","journal-title":"Am J Med"},{"key":"2026102519571669700_ehag098-B759","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa023204","article-title":"The prevention of radiocontrast-agent-induced nephropathy by hemofiltration","volume":"349","author":"Marenzi","year":"2003","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B760","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/s0002-9343(01)00983-4","article-title":"Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful","volume":"111","author":"Vogt","year":"2001","journal-title":"Am J Med"},{"key":"2026102519571669700_ehag098-B761","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","article-title":"Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis","volume":"180","author":"Woolen","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026102519571669700_ehag098-B762","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1148\/radiol.2019182916","article-title":"A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis","volume":"292","author":"Attari","year":"2019","journal-title":"Radiology"},{"key":"2026102519571669700_ehag098-B763","doi-asserted-by":"publisher","first-page":"110","DOI":"10.7326\/M20-0299","article-title":"Risk for nephrogenic systemic fibrosis after exposure to newer gadolinium agents: a systematic review","volume":"173","author":"Lunyera","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026102519571669700_ehag098-B764","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12350-012-9654-2","article-title":"The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation","volume":"20","author":"Doukky","year":"2013","journal-title":"J Nucl Cardiol"},{"key":"2026102519571669700_ehag098-B765","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.amjcard.2009.08.663","article-title":"Safety of regadenoson in patients with end-stage renal disease","volume":"105","author":"Aljaroudi","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B766","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10554-012-0166-6","article-title":"Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease\u2013the ASSUAGE-CKD trial","volume":"29","author":"Doukky","year":"2013","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026102519571669700_ehag098-B767","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41581-021-00418-2","article-title":"Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative","volume":"17","author":"Prowle","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2026102519571669700_ehag098-B768","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrneph.2017.119","article-title":"Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment","volume":"13","author":"Wang","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2026102519571669700_ehag098-B769","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s13054-023-04640-1","article-title":"Prevention of cardiac surgery-associated acute kidney injury: a systematic review and meta-analysis of non-pharmacological interventions","volume":"27","author":"Hariri","year":"2023","journal-title":"Crit Care"},{"key":"2026102519571669700_ehag098-B770","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.960581","article-title":"Strategies for post-cardiac surgery acute kidney injury prevention: a network meta-analysis of randomized controlled trials","volume":"9","author":"Chen","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026102519571669700_ehag098-B771","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bja.2020.06.064","article-title":"Pharmacological interventions for the prevention of renal injury in surgical patients: a systematic literature review and meta-analysis","volume":"126","author":"Pathak","year":"2021","journal-title":"Br J Anaesth"},{"key":"2026102519571669700_ehag098-B772","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.jcin.2023.06.015","article-title":"Validation of a contemporary acute kidney injury risk score in patients with acute coronary syndrome","volume":"16","author":"Landi","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"2026102519571669700_ehag098-B773","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.amjcard.2015.02.004","article-title":"Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention","volume":"115","author":"Jurado-Roman","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B774","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ-2021-068247","article-title":"Sex differences in mortality among binational cohort of people with chronic kidney disease: population based data linkage study","volume":"375","author":"De La Mata","year":"2021","journal-title":"BMJ"},{"key":"2026102519571669700_ehag098-B775","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/CIRCRESAHA.122.321751","article-title":"Accelerated vascular aging in chronic kidney disease: the potential for novel therapies","volume":"132","author":"Hobson","year":"2023","journal-title":"Circ Res"},{"key":"2026102519571669700_ehag098-B776","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2215\/CJN.04290510","article-title":"Large artery calcification on dialysis patients is located in the intima and related to atherosclerosis","volume":"6","author":"Coll","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B777","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.kint.2020.01.046","article-title":"Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Flythe","year":"2020","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B778","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1046\/j.1523-1755.1998.00154.x","article-title":"Long-term evolution of cardiomyopathy in dialysis patients","volume":"54","author":"Foley","year":"1998","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B779","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(16)30508-6","article-title":"The heart and vascular system in dialysis","volume":"388","author":"Wanner","year":"2016","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B780","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1161\/CIRCRESAHA.123.321763","article-title":"Role of the microbiome in gut-heart-kidney cross talk","volume":"132","author":"Glorieux","year":"2023","journal-title":"Circ Res"},{"key":"2026102519571669700_ehag098-B781","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa1103313","article-title":"Long interdialytic interval and mortality among patients receiving hemodialysis","volume":"365","author":"Foley","year":"2011","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B782","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/ndt\/gfab023","article-title":"Asystole episodes and bradycardia in patients with end-stage renal disease","volume":"37","author":"Rautavaara","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B783","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.kint.2017.11.019","article-title":"Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle","volume":"93","author":"Roy-Chaudhury","year":"2018","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B784","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.kint.2023.05.019","article-title":"Managing the symptom burden associated with maintenance dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"104","author":"Mehrotra","year":"2023","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B785","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.kint.2023.01.006","article-title":"Home dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"103","author":"Perl","year":"2023","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B786","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.kint.2019.01.017","article-title":"Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"96","author":"Chan","year":"2019","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B787","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B788","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jchf.2021.04.005","article-title":"Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy","volume":"9","author":"Jhund","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026102519571669700_ehag098-B789","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B790","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B791","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B792","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ"},{"key":"2026102519571669700_ehag098-B793","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030142","article-title":"Adverse effects of aldosterone: beyond blood pressure","volume":"13","author":"Brown","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B794","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013109.pub2","article-title":"Aldosterone antagonists for people with chronic kidney disease requiring dialysis","volume":"2","author":"Hasegawa","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B795","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0140-6736(25)01153-5","article-title":"Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"406","author":"Pyne","year":"2025","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B796","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","article-title":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial","volume":"406","author":"Walsh","year":"2025","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B797","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2215\/CJN.06370615","article-title":"Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis","volume":"11","author":"Parfrey","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B798","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1681\/ASN.2021101327","article-title":"Interventions to attenuate vascular calcification progression in chronic kidney disease: a systematic review of clinical trials","volume":"33","author":"Xu","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"10464","key":"2026102519571669700_ehag098-B799","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/S0140-6736(24)01859-2","article-title":"Haemodiafiltration versus haemodialysis for kidney failure: an individual patient data meta-analysis of randomised controlled trials","volume":"404","author":"Vernooij","year":"2024","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B800","doi-asserted-by":"publisher","first-page":"205","DOI":"10.34067\/KID.0000000000000360","article-title":"Cardiovascular outcomes in patients on home hemodialysis and peritoneal dialysis","volume":"5","author":"Shah","year":"2024","journal-title":"Kidney360"},{"key":"2026102519571669700_ehag098-B801","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000001088","article-title":"Cardiovascular effects of home dialysis therapies: a scientific statement from the American Heart Association","volume":"146","author":"Sarnak","year":"2022","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B802","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/ckj\/sfaa078","article-title":"An update review of intradialytic hypotension: concept, risk factors, clinical implications and management","volume":"13","author":"Kanbay","year":"2020","journal-title":"Clin Kidney J"},{"key":"2026102519571669700_ehag098-B803","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1001\/jama.298.11.1291","article-title":"Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial","volume":"298","author":"Culleton","year":"2007","journal-title":"JAMA"},{"key":"2026102519571669700_ehag098-B804","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1056\/NEJMoa1001593","article-title":"In-center hemodialysis six times per week versus three times per week","volume":"363","author":"FHN Trial Group","year":"2010","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B805","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/hdi.12255","article-title":"Effects of frequent hemodialysis on blood pressure: results from the randomized frequent hemodialysis network trials","volume":"19","author":"Kotanko","year":"2015","journal-title":"Hemodial Int"},{"key":"2026102519571669700_ehag098-B806","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","article-title":"Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis","volume":"406","author":"Rossignol","year":"2025","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B807","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/j.1600-6143.2011.03686.x","article-title":"Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes","volume":"11","author":"Tonelli","year":"2011","journal-title":"Am J Transplant"},{"key":"2026102519571669700_ehag098-B808","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1681\/ASN.2020050566","article-title":"Death after kidney transplantation: an analysis by era and time post-transplant","volume":"31","author":"Ying","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B809","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO Clinical Practice Guideline on the evaluation and management of candidates for kidney transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"2026102519571669700_ehag098-B810","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","article-title":"2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery","volume":"43","author":"Halvorsen","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B811","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/ki.2014.335","article-title":"Cardiovascular risk assessment in kidney transplantation","volume":"87","author":"Hart","year":"2015","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B812","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jacc.2012.05.008","article-title":"Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"60","author":"Lentine","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B813","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1161\/CIR.0000000000001104","article-title":"Emerging evidence on coronary heart disease screening in kidney and liver transplantation candidates: a scientific statement from the American Heart Association: endorsed by the American Society of Transplantation","volume":"146","author":"Cheng","year":"2022","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B814","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031150","article-title":"External validation of proposed American Heart Association algorithm for cardiovascular screening before kidney transplantation","volume":"12","author":"Nielsen","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B815","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1097\/TP.0000000000000992","article-title":"Coronary calcium score may replace cardiovascular risk factors as primary risk stratification tool before kidney transplantation","volume":"100","author":"Winther","year":"2016","journal-title":"Transplantation"},{"key":"2026102519571669700_ehag098-B816","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jcmg.2017.07.012","article-title":"Prognostic value of risk factors, calcium score, coronary CTA, myocardial perfusion imaging, and invasive coronary angiography in kidney transplantation candidates","volume":"11","author":"Winther","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026102519571669700_ehag098-B817","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.ajt.2023.05.001","article-title":"In a real-life setting, risk factors, coronary artery calcium score, and coronary stenosis at computed tomography angiography are associated with major adverse cardiovascular events and all-cause mortality among kidney transplant candidates","volume":"23","author":"Nielsen","year":"2023","journal-title":"Am J Transplant"},{"key":"2026102519571669700_ehag098-B818","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s12350-013-9761-8","article-title":"Hybrid myocardial imaging for risk stratification prior to kidney transplantation: added value of coronary calcium and epicardial adipose tissue","volume":"20","author":"Karohl","year":"2013","journal-title":"J Nucl Cardiol"},{"key":"2026102519571669700_ehag098-B819","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.amjcard.2016.02.003","article-title":"Prognostic utility of calcium scoring as an adjunct to stress myocardial perfusion scintigraphy in end-stage renal disease","volume":"117","author":"Moody","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B820","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/TP.0000000000000611","article-title":"Prognostic value of cardiac tests in potential kidney transplant recipients: a systematic review","volume":"99","author":"Wang","year":"2015","journal-title":"Transplantation"},{"key":"2026102519571669700_ehag098-B821","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.124.017066","article-title":"Coronary plaque characteristics in patients with chronic kidney failure: impact on cardiovascular events and mortality","volume":"17","author":"Dahl","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026102519571669700_ehag098-B822","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jcmg.2014.12.028","article-title":"Diagnostic performance of coronary CT angiography and myocardial perfusion imaging in kidney transplantation candidates","volume":"8","author":"Winther","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026102519571669700_ehag098-B823","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.kint.2020.10.019","article-title":"A propensity score-matched analysis indicates screening for asymptomatic coronary artery disease does not predict cardiac events in kidney transplant recipients","volume":"99","author":"Nimmo","year":"2021","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B824","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jamainternmed.2022.6069","article-title":"Association of pretransplant coronary heart disease testing with early kidney transplant outcomes","volume":"183","author":"Cheng","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2026102519571669700_ehag098-B825","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023548","article-title":"Coronary revascularization versus optimal medical therapy in renal transplant candidates with coronary artery disease: a systematic review and meta-analysis","volume":"11","author":"Siddiqui","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B826","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jacc.2021.05.001","article-title":"Kidney transplant list status and outcomes in the ISCHEMIA-CKD trial","volume":"78","author":"Herzog","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026102519571669700_ehag098-B827","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1056\/NEJMoa041905","article-title":"Coronary-artery revascularization before elective major vascular surgery","volume":"351","author":"McFalls","year":"2004","journal-title":"N Engl J Med"},{"key":"2026102519571669700_ehag098-B828","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.amjcard.2008.12.018","article-title":"Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V pilot study)","volume":"103","author":"Schouten","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026102519571669700_ehag098-B829","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1093\/eurheartj\/ehab246","article-title":"Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis","volume":"42","author":"Navarese","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B830","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/0140-6736(92)93010-k","article-title":"Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure","volume":"340","author":"Manske","year":"1992","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2026102519571669700_ehag098-B831","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/ajt.14557","article-title":"OPTN\/SRTR 2016 Annual Data Report: Kidney","volume":"18","author":"Hart","year":"2018","journal-title":"Am J Transplant"},{"key":"2026102519571669700_ehag098-B832","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1053\/j.ajkd.2019.10.001","article-title":"Screening for asymptomatic coronary artery disease in waitlisted kidney transplant candidates: a cost-utility analysis","volume":"75","author":"Ying","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B833","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ahj.2019.05.008","article-title":"Canadian-Australasian randomised trial of screening kidney transplant candidates for coronary artery disease\u2013a trial protocol for the CARSK study","volume":"214","author":"Ying","year":"2019","journal-title":"Am Heart J"},{"key":"2026102519571669700_ehag098-B834","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1161\/CIRCULATIONAHA.115.008718","article-title":"Worldwide exposures to cardiovascular risk factors and associated health effects: current knowledge and data gaps","volume":"133","author":"Tzoulaki","year":"2016","journal-title":"Circulation"},{"key":"2026102519571669700_ehag098-B835","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1053\/j.ajkd.2004.03.013","article-title":"Hypertension after kidney transplantation","volume":"43","author":"Kasiske","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B836","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/s0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Rahimi","year":"2021","journal-title":"Lancet"},{"key":"2026102519571669700_ehag098-B837","doi-asserted-by":"publisher","first-page":"10507","DOI":"10.1038\/s41598-019-46991-2","article-title":"Intensive blood pressure control is associated with improved patient and graft survival after renal transplantation","volume":"9","author":"Pagonas","year":"2019","journal-title":"Sci Rep"},{"key":"2026102519571669700_ehag098-B838","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1111\/j.1600-6143.2005.01093.x","article-title":"Improved long-term outcomes after renal transplantation associated with blood pressure control","volume":"5","author":"Opelz","year":"2005","journal-title":"Am J Transplant"},{"key":"2026102519571669700_ehag098-B839","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.transproceed.2022.12.010","article-title":"Impact of blood pressure control on graft survival in kidney transplant recipients","volume":"55","author":"Agarwal","year":"2023","journal-title":"Transplant Proc"},{"key":"2026102519571669700_ehag098-B840","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/ajh\/hpz095","article-title":"Blood pressure, chronic kidney disease progression, and kidney allograft failure in kidney transplant recipients: a secondary analysis of the FAVORIT trial","volume":"32","author":"Malhotra","year":"2019","journal-title":"Am J Hypertens"},{"key":"2026102519571669700_ehag098-B841","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023300","article-title":"Cardiovascular effects of autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal in renal transplant recipients: an analysis of the randomized TRITON study","volume":"10","author":"Meucci","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B842","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/TP.0b013e3182958552","article-title":"Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients","volume":"96","author":"Mourer","year":"2013","journal-title":"Transplantation"},{"key":"2026102519571669700_ehag098-B843","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1111\/j.1523-1755.2005.00349.x","article-title":"New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation","volume":"67","author":"Cosio","year":"2005","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B844","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/sj.ki.5000116","article-title":"The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events","volume":"69","author":"Hjelmesaeth","year":"2006","journal-title":"Kidney Int"},{"key":"2026102519571669700_ehag098-B845","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabet.2010.09.003","article-title":"New-onset diabetes after transplantation: risk factors and clinical impact","volume":"37","author":"Rakel","year":"2011","journal-title":"Diabetes Metab"},{"key":"2026102519571669700_ehag098-B846","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009966.pub3","article-title":"Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients","volume":"8","author":"Lo","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B847","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/ndt\/gfad258","article-title":"International consensus on post-transplantation diabetes mellitus","volume":"39","author":"Sharif","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B848","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14947","article-title":"Post-kidney transplant body mass index trajectories are associated with graft loss and mortality","volume":"37","author":"Liu","year":"2023","journal-title":"Clin Transplant"},{"key":"2026102519571669700_ehag098-B849","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/ndt\/gfv214","article-title":"Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis","volume":"30","author":"Hill","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B850","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15368","article-title":"Oxalate nephropathy after kidney transplantation: risk factors and outcomes of two phenotypes","volume":"38","author":"Garg","year":"2024","journal-title":"Clin Transplant"},{"key":"2026102519571669700_ehag098-B851","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000334732","article-title":"Pretransplant physical activity predicts all-cause mortality in kidney transplant recipients","volume":"35","author":"Rosas","year":"2012","journal-title":"Am J Nephrol"},{"key":"2026102519571669700_ehag098-B852","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5414\/cnp65401","article-title":"Excess risk of renal allograft loss and early mortality among elderly recipients is associated with poor exercise capacity","volume":"65","author":"Yango","year":"2006","journal-title":"Clin Nephrol"},{"key":"2026102519571669700_ehag098-B853","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2215\/CJN.03340410","article-title":"Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients","volume":"6","author":"Zelle","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B854","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/ndt\/gfaa038","article-title":"Physical activity and risk of cardiovascular events and all-cause mortality among kidney transplant recipients","volume":"35","author":"Kang","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B855","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003598.pub3","article-title":"Antihypertensive treatment for kidney transplant recipients","volume":"7","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102519571669700_ehag098-B856","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/ndt\/gfz092","article-title":"Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis","volume":"35","author":"Pisano","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519571669700_ehag098-B857","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/HJH.0000000000003663","article-title":"Blood pressure lowering for kidney transplant recipients: systematic review with network meta-analysis","volume":"42","author":"Natale","year":"2024","journal-title":"J Hypertens"},{"key":"2026102519571669700_ehag098-B858","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"2026102519571669700_ehag098-B859","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation"},{"key":"2026102519571669700_ehag098-B860","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.ekir.2024.05.022","article-title":"Cardioprotective effect of SGLT2 inhibitor in diabetic kidney transplant recipients: a multicenter propensity score matched study","volume":"9","author":"Lim","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026102519571669700_ehag098-B861","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/tri.13599","article-title":"Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single-center cohort study","volume":"33","author":"Bixby","year":"2020","journal-title":"Transpl Int"},{"key":"2026102519571669700_ehag098-B862","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1097\/TP.0000000000003168","article-title":"Efficacy and safety of direct oral anticoagulants in kidney transplantation: a single-center pilot experience","volume":"104","author":"Leon","year":"2020","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"2026102519571669700_ehag098-B863","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO Clinical Practice Guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes Transplant Work Group","year":"2009","journal-title":"Am J Transplant"},{"key":"2026102519571669700_ehag098-B864","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1097\/TP.0000000000004945","article-title":"Glucagon-like peptide 1 receptor agonists and cardiovascular outcomes in solid organ transplant recipients with diabetes mellitus","volume":"108","author":"Dotan","year":"2024","journal-title":"Transplantation"},{"key":"2026102519571669700_ehag098-B865","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae044","article-title":"Sex disparities in mortality and cardiovascular outcomes in chronic kidney disease","volume":"17","author":"Balafa","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026102519571669700_ehag098-B866","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1053\/j.ajkd.2024.04.013","article-title":"Sex and the risk of atheromatous and nonatheromatous cardiovascular disease in CKD: findings from the CKD-REIN cohort study","volume":"84","author":"Faucon","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B867","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029691","article-title":"Sex differences in cardiovascular outcomes in patients with kidney failure","volume":"13","author":"Shah","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026102519571669700_ehag098-B868","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/ckj\/sfad018","article-title":"Women\u2019s representation in clinical trials of patients with chronic kidney disease","volume":"16","author":"Pinho-Gomes","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026102519571669700_ehag098-B869","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13063-016-1354-9","article-title":"Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND)","volume":"17","author":"Aung","year":"2016","journal-title":"Trials"},{"key":"2026102519571669700_ehag098-B870","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41581-024-00854-w","article-title":"Treatment of chronic kidney disease in older populations","volume":"20","author":"Kishi","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026102519571669700_ehag098-B871","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/j.ekir.2022.06.015","article-title":"Living well with kidney disease and effective symptom management: consensus conference proceedings","volume":"7","author":"Rhee","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026102519571669700_ehag098-B872","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2024.1419731","article-title":"Psychological risk factors and cardiovascular disease","volume":"15","author":"Carola","year":"2024","journal-title":"Front Psychol"},{"key":"2026102519571669700_ehag098-B873","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.100910","article-title":"The role of the clinical psychologist in the care of adults with cardiovascular disease","volume":"3","author":"Smolderen","year":"2024","journal-title":"JACC Adv"},{"key":"2026102519571669700_ehag098-B874","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ekir.2016.09.005","article-title":"Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management","volume":"2","author":"Shirazian","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2026102519571669700_ehag098-B875","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2023.200199","article-title":"Depression and incident cardiovascular disease among patients with chronic kidney disease","volume":"18","author":"D\u2019Oro","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"2026102519571669700_ehag098-B876","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100149","article-title":"Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: a prospective analysis using data from the UK Biobank","volume":"8","author":"Ronaldson","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"2026102519571669700_ehag098-B877","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12882-023-03447-0","article-title":"Effect of psychosocial interventions for depression in adults with chronic kidney disease: a systematic review and meta-analysis","volume":"25","author":"Yang","year":"2024","journal-title":"BMC Nephrol"},{"key":"2026102519571669700_ehag098-B878","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2331613","article-title":"Effectiveness of psychoeducational interventions on psychological distress and health-related quality of life among patients with maintenance hemodialysis: a systematic review and meta-analysis","volume":"46","author":"Zhang","year":"2024","journal-title":"Ren Fail"},{"key":"2026102519571669700_ehag098-B879","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3389\/fpsyg.2017.00992","article-title":"Psychosocial interventions for depressive and anxiety symptoms in individuals with chronic kidney disease: systematic review and meta-analysis","volume":"8","author":"Pascoe","year":"2017","journal-title":"Front Psychol"},{"key":"2026102519571669700_ehag098-B880","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004675","article-title":"Do psychological interventions reduce depression in hemodialysis patients?: A meta-analysis of randomized controlled trials following PRISMA","volume":"95","author":"Xing","year":"2016","journal-title":"Medicine"},{"key":"2026102519571669700_ehag098-B881","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1093\/eurheartj\/ehaf191","article-title":"2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease: developed under the auspices of the ESC Clinical Practice Guidelines Committee","volume":"46","author":"Bueno","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102519571669700_ehag098-B882","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2215\/CJN.09960917","article-title":"Person-centered integrated care for chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Valentijn","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026102519571669700_ehag098-B883","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ejim.2015.07.002","article-title":"Multidisciplinary care in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"26","author":"Wang","year":"2015","journal-title":"Eur J Intern Med"},{"key":"2026102519571669700_ehag098-B884","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1053\/j.ajkd.2021.08.021","article-title":"Challenges to shared decision making about treatment of advanced CKD: a qualitative study of patients and clinicians","volume":"79","author":"House","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026102519571669700_ehag098-B885","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae331","article-title":"Integrated, person-centred care for patients with complex cardiovascular disease, diabetes mellitus and chronic kidney disease: a randomized trial","volume":"17","author":"Even","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026102519571669700_ehag098-B886","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/clc.23307","article-title":"Palliative cardiovascular care: the right patient at the right time","volume":"43","author":"Sullivan","year":"2020","journal-title":"Clin Cardiol"},{"key":"2026102519571669700_ehag098-B887","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1225823","article-title":"Consensus document on palliative care in cardiorenal patients","volume":"10","author":"Bonanad","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026102519571669700_ehag098-B888","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/ki.2015.110","article-title":"Executive summary of the KDIGO Controversies Conference on supportive care in chronic kidney disease: developing a roadmap to improving quality care","volume":"88","author":"Davison","year":"2015","journal-title":"Kidney Int"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag098\/70763431\/ehag098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag098\/70763431\/ehag098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T23:58:33Z","timestamp":1792972713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag098\/8766283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":888,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag098","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"ehag098"}}